



Rec'd PCT/PTO 17 DEC 2004
PCT/GB 2003 / 002582

GB03/002582
10/518427
INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 15 AUG 2003


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed


Dated

P. Mahoney
3 July 2003

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)



20 JUN 02 07:27:50Z-1 D02246
POL/7700 0.00-0214267.7

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference		P014447GB DAA	
2. Patent application number (The Patent Office will fill in this part)		0214267.7	
3. Full name, address and postcode of the or of each applicant (underline all surnames)		IC Vec Limited GTC - Imperial College, Flowers Building Armstrong Road South Kensington London SW7 2AY Patents ADP number (if you know it) 8281461001 If the applicant is a corporate body, give the country/state of its incorporation United Kingdom	
4. Title of the invention		COMPOUND	
5. Name of your agent (if you have one)		D Young & Co	
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)		21 New Fetter Lane London EC4A 1DA Patents ADP number (if you know it) 59006	
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:		Yes	
a) any applicant named in part 3 is not an inventor, or			
b) there is an inventor who is not named as an applicant, or			
c) any named applicant is a corporate body.			
See note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 61

Claim(s) 6

Abstract 1

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents 0
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

D Young & Co (Agents for the Applicants)

Date 20 June 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

David Alcock

023 8071 9500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.

If you are not sure what to do, please contact the Patent Office.

COMPOUND

The present invention relates to a compound. In particular the present invention relates to a compound having pharmaceutical activity

5

WO01/68582 relates to fatty acid analogues. Further, WO01/68582 relates to the use of the fatty acid analogues for the treatment and/or prevention of syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis. WO01/68582 also relates to processes for the preparation of the novel fatty acid
10 analogues.

As discussed in WO01/68582, EP-A-0345038 describes the use of non-oxidizable fatty acid analogues of the formula; $\text{Alkyl-X-CH}_2\text{COOR}$ wherein the alkyl is a saturated or unsaturated hydrocarbon chain of 8 to 22 carbon atoms, X represents a O, S, SO or
15 SO_2 , and R is hydrogen or a C1-C4 alkyl group, for the treatment of hyperlipaemic conditions and for the reducing the concentration of cholesterol and triglycerides in the blood of mammals.

PCT/N095/00195 describes alkyl-S- CH_2COOR and alkyl-Se- CH_2COOR for the inhibition
20 of the oxidative modification of LDL. Further, this application describes the use of the selenium-compound for the treatment of hyperlipaemic condition and for reducing the concentration of cholesterol and triglycerides.

The PCT applications PCT/N099/00135, PCT/N099/00136 and PCT/N099/00149
25 describes fatty acid analogues of the formula (I) $\text{CH}_3\text{-(CH}_2\text{)}_m\text{-(Xi-CH}_2\text{)}_n\text{-COOR-}$ wherein n is an integer from 1 to 12, and -wherein m is an integer from 0 to 23, and -wherein i is an odd number which indicates the position relative to COOR, and -wherein Xi independent of each other are selected from the group comprising O, S, SO, SO_2 , Se and CH_2 , and -wherein R represents hydrogen or C1-C4 alkyl, - with the proviso that at least one of the
30 Xi is not CH_2 , or a salt, prodrug or complex thereof. This formula comprises one or several X groups (preferably selenium and sulphur) in positions 3, 5, 7, 9, etc.

Further, these PCT applications describe several medicinal and nutritional applications.

PCT/N099/00135 describes the use of the fatty acid analogues the treatment and/or prevention of obesity, hypertension, fatty liver and the multi metabolic syndrome termed metabolic syndrome or Syndrome X. Further, this application describes a method for the treatment or prevention of an obese or overweight condition, and a method for producing
5 weigh loss or a reduction of the fat mass in a human or non-human animal. The application also describes a nutritional composition effective to reduce, or to prevent an increase in, the total body weight or the total body fat mass in a human or non-human animal, and also a method for the modification of the fat distribution and content of animals in order to improve the quality of the meat, or product such as milk and eggs.

10

PCT/N099/00136 describes use of fatty acid analogues for the treatment and/or prevention of diabetes (both type I and II), and a method for the treatment or prevention of hyperglycaemia, hyperinsulinemia and reduced sensitivity to insulin. A nutritional composition effective to reduce, or to prevent an increase in the concentration of glucose
15 in the blood of a human or non-human animal is also disclosed, as is a method for reducing the concentration of glucose in the blood of a human or non-human animal.

PCT/N099/00149 describes the use of the fatty acid analogues for the treatment and/or prevention of primary and/or secondary stenosis, and/or a disease caused by procedural
20 vascular trauma and/or pathological proliferation of smooth muscle cells, and/or an increased level of plasma homocystein.

Aspects of the invention are defined in the appended claims.

25 In one aspect the present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X-Y-Z- wherein X is a hydrocarbonyl chain, Y is selected from at least one of S, Se, SO₂, SO, O, CH₂, and Z is an optional hydrocarbonyl group, wherein when Y is CH₂, the chain X-Y-Z contains an even number of atoms; wherein the polar moiety is of the formula -
30 [C(O)]_mPHG wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

In a further aspect the present invention provides a combination comprising a liposome and a compound according to the present invention or a micelle containing a compound
35 according to the present invention.

In a further aspect the present invention provides a pharmaceutical composition comprising a compound according to the present invention or a combination according to the present invention optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.


In a further aspect the present invention provides use of a compound according to the present invention or a combination according to the present invention in medicine.

10 In a further aspect the present invention provides use of a compound according to the present invention in the manufacture of a medicament for the treatment and/or prevention of a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis.


15 In a further aspect the present invention provides use of a compound according to the present invention in the manufacture of a medicament for lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein.

20 In a further aspect the present invention provides a method for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound according to the present invention

25 We have identified new lipid derivatives, such as phospholipids derivatives, (and in particular phosphatidyl cholines 1 and ethanolamines 2) that may be of use in various therapeutic applications.




Phosphatidylcholine 1




Phosphatidylethanolamine 2

Y = S, SO, SO₂, O, Se or CH₂
 Y¹ = S, SO, SO₂, O, Se or CH₂
 R = alkyl, alkenyl or alkynyl
 R¹ = alkyl, alkenyl or alkynyl


These lipids will incorporate the known^{1a-d} sulphur fatty acid, tetradecylthioacetic acid (TTA, 3) as well as its unsaturated analogues, dTTA 4 and tTTA 5. It is understood that analogues which contain one of Se, SO, SO₂, O or CH₂ in place of sulphur will also provide useful pharmaceutical activity. In addition the length and degrees of saturation of the alkyl chains can also be varied.



TTA 3



dTTA 4



tTTA 5

TTA is a modified fatty acid which has a number of powerful effects demonstrable both *in vivo* and *in vitro* on living organisms.^{1a-d,2,3} It has properties very similar to natural fatty

acids, the main difference being that TTA cannot be oxidised by the mitochondrial β -oxidation, but significantly increases the oxidation of other fatty acids. Despite the fact that TTA is not able to undergo β -oxidation, it is metabolised in most ways as a normal saturated fatty acid, but has a strong preference to being incorporated into phospholipids.^{1a-d,2,3}

TTA affects antioxidant status at different levels by having the potential of changing the antioxidant defence system in addition to being an antioxidant itself through its free radical scavenging capacity. Addition of TTA may prevent the oxidative modification of LDL particles in plasma and reduce the generation of lipid peroxides.^{1a-d,2,3}

The sulphur atom is more electronegative than carbon. Hence, the 3-thia acid is slightly more acidic than its corresponding fatty acid. Thia fatty acids are also more polar and slightly more soluble in water than fatty acids of corresponding chain length.

15

The parent fatty acids derivative used in the present novel compounds have one or more of the following therapeutic effects. This is confirmed by the reference give:

- 1) The treatment of hyperlipidaemic conditions and the reduction of concentration of cholesterol and triglycerides in the blood of mammals. Selenium analogues also show such properties as well as the inhibition of oxidative modification LDL.^{4,5}
- 2) The treatment of and /or prevention of obesity, hypertention, fatty liver and multi metabolic syndrome (Syndrome X).^{1b}
- 3) The treatment and/or the prevention of diabetes (Type I and II), hyperglycaemia, hyperinsulinemia, and reduced sensitivity to insulin.^{1c}
- 4) The treatment and/or prevention of primary stenosis, secondary stenosis, and a disease caused by proceural vascular trauma and pathological proliferation of smooth muscle cells, and increase level of plasma homocystein.^{1d}
- 5) The treatment or prevention of cancer. More specifically, treatment and/or prevention of primary and secondary neoplasms.⁶

30

The fatty acid lipid derivatives of the present invention have corresponding therapeutic effects.

For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each

35

section are not necessarily limited to each particular section.

PREFERABLE ASPECTS

5 POLAR MOIETY

Polar Head Group (PHG)

10 It will be appreciated by one of skill in the art that the polar head group may be derived from a suitable lipid. By the term "lipid" it may be meant a compound based on a fatty acids or a closely related compounds such as their corresponding alcohol or sphingosine base.

15 In one preferred aspect the polar head group is derived from phospholipids, ceramides, triacylglycerols, lysophospholipids, phosphatidylserines, glycerols, alcohols, alkoxy compounds, monoacylglycerols, gangliosides, sphingomyelins, cerebroside, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols (PI), diacylglycerols, Phosphatidic acids, glycerocarbohydrates, polyalcohols and phosphatidylglycerols.

20

In one preferred aspect the polar head group is derived from phospholipids, ceramides, triacylglycerols, lysophospholipids and phosphatidylserines.

Preferably the polar head group is derived from of a phospholipid.

25

Preferably the phospholipid is a neutral or anionic phospholipid.

30 In one preferred aspect the polar head group is derived from a phospholipid selected from a phosphatidylcholine (PC), a phosphatidylethanolamine (PE) such as Dioleoylphosphatidyl-ethanolamine (DOPE), and combinations thereof.

In one aspect the polar head group (PHG) may be the group -W-Linker-HG, wherein W is selected from CH₂, O, NR¹ and S, wherein R¹ is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.

35

The head group (HG) may be polar or non-polar. When HG is non-polar it may be rendered polar by group -C(O)W-Linker-. Such head groups are encompassed by the present definition provided -C(O)W-Linker-HG is polar and HG is polar when attached to the -C(O)W-Linker- group.

5

In one aspect the head group (HG) may be an alkyl group. In this aspect preferably the alkyl contains at least 5 carbon, for example it is a C₅₋₁₀₀ alkyl group, a C₅₋₈₀ alkyl group, a C₅₋₆₀ alkyl group, a C₅₋₅₀ alkyl group, a C₅₋₄₀ alkyl group, a C₅₋₃₀ alkyl group or a C₅₋₂₀ alkyl group.

10

In one aspect the head group (HG) is derived from phospholipids, ceramides, triacylglycerols, lysophospholipids, phosphatidylserines, glycerols, alcohols, alkoxy compounds, monoacylglycerols, gangliosides, sphingomyelins, cerebrosides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols (PI), diacylglycerols, Phosphatidic acids, glycerocarbohydrates, polyalcohols and phosphatidylglycerols.

15

Linker

20 The linker of -W-Linker-HG may be any suitable group. A typical linker group is a hydrocarbyl group.

The term "hydrocarbyl group" as used herein means a group comprising at least C and H and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen and oxygen. A non-limiting example of a hydrocarbyl group is an acyl group.

25

A typical hydrocarbyl group is a hydrocarbon group. Here the term "hydrocarbon" means any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be

35

linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

In one preferred aspect at least one optional linker group is not present. In one preferred aspect no optional linker groups are present.

- 10 When one or more or all optional linker groups are not present, the group/compound from which the polar head group is derived is typically chosen to have one or more -OH groups. These allow a simple ester bond between the non-polar moiety and the polar moiety to be provided.
- 15 It will be appreciated by one skilled in the art that when an optional linker is present two or more W groups may or may not be bonded to the same atom of the linker. It is envisaged that in some aspects the two or more W groups are bonded to different atoms of a linker.

20 W

W of -W-Linker-HG is selected from CH₂, O, NR¹ and S, wherein R¹ is H or a hydrocarbyl group.

- 25 In one preferred aspect W is O or NR¹.

R¹ is preferably H or a hydrocarbon group.

R¹ is preferably H, C₁₋₃₀, C₁₋₂₅, C₁₋₂₀, C₁₋₁₅, C₁₋₁₀, C₁₋₅, or C₅₋₁₅ hydrocarbyl group.

30

R¹ is preferably H, C₁₋₃₀, C₁₋₂₅, C₁₋₂₀, C₁₋₁₅, C₁₋₁₀, C₁₋₅, or C₅₋₁₅ hydrocarbon group.

R¹ is preferably H, C₁₋₃₀, C₁₋₂₅, C₁₋₂₀, C₁₋₁₅, C₁₋₁₀, C₁₋₅, or C₅₋₁₅ optionally substituted alkyl group.

35

R¹ is preferably H, C₁₋₃₀, C₁₋₂₅, C₁₋₂₀, C₁₋₁₅, C₁₋₁₀, C₁₋₅, or C₅₋₁₅ unsubstituted alkyl group.

NON-POLAR MOIETY

X

5

As discussed above X is a hydrocarbyl chain. By "hydrocarbyl chain" it is meant a linear hydrocarbyl group.

10

In the following definitions of chain length it is meant the longest chain of directly bonded atoms within moiety X. It will be understood that a chain does not include atoms of cyclic substituents or substituents of a terminal carbon.

In one preferred aspect X is a group selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.

15

In one preferred aspect X is a group selected from optionally substituted C₆-C₂₄ alkyl, optionally substituted C₆-C₂₄ alkenyl and optionally substituted C₆-C₂₄ alkynyl.

20

In one preferred aspect X is a group selected from optionally substituted alkyl having a chain length of 6 to 24 atoms, optionally substituted alkenyl having a chain length of 6 to 24 atoms and optionally substituted alkynyl having a chain length of 6 to 24 atoms.

25

In one preferred aspect X is a group selected from optionally substituted alkyl having a chain length of 10 to 18 atoms, optionally substituted alkenyl having a chain length of 10 to 18 atoms and optionally substituted alkynyl having a chain length of 10 to 18 atoms.

30

In one preferred aspect X is a group selected from optionally substituted alkyl having a chain length of 14 atoms, optionally substituted alkenyl having a chain length of 14 atoms and optionally substituted alkynyl having a chain length of 14 atoms.

35

In one preferred aspect X is a group selected from unsubstituted alkyl, unsubstituted alkenyl and unsubstituted alkynyl.

In one preferred aspect X is a group selected from unsubstituted C₆-C₂₄ alkyl, unsubstituted C₆-C₂₄ alkenyl and unsubstituted C₆-C₂₄ alkynyl.

In one preferred aspect X is a group selected from unsubstituted alkyl having a chain length of 6 to 24 atoms, unsubstituted alkenyl having a chain length of 6 to 24 atoms and unsubstituted alkynyl having a chain length of 6 to 24 atoms.

5

In one preferred aspect X is a group selected from unsubstituted C₁₀-C₁₈ alkyl, unsubstituted C₁₀-C₁₈ alkenyl and unsubstituted C₁₀-C₁₈ alkynyl.

10

In one preferred aspect X is a group selected from unsubstituted alkyl having a chain length of 10 to 18 atoms, unsubstituted alkenyl having a chain length of 10 to 18 atoms and unsubstituted alkynyl having a chain length of 10 to 18 atoms.

In one preferred aspect X is a group selected from unsubstituted C₁₄ alkyl, unsubstituted C₁₄ alkenyl and unsubstituted C₁₄ alkynyl.

15

In one preferred aspect X is a group selected from unsubstituted alkyl having a chain length of 14 atoms, unsubstituted alkenyl having a chain length of 14 atoms and unsubstituted alkynyl having a chain length of 14 atoms.

20

In one preferred aspect X is a hydrocarbon chain. By "hydrocarbon chain" it is meant a linear hydrocarbon group.

25

In one aspect X is selected from C₆-C₂₄ alkenyl containing one or more double bonds and optionally one or more triple bonds, C₆-C₂₄ alkynyl, C₆-C₂₄ alkyl optionally substituted with at least one of F, Cl, hydroxy, C₁-C₄ alkoxy, C₁-C₄ alkylthio, C₂-C₅ acyloxy and C₁-C₄ alkyl.

30

One skilled in the art will appreciate that alkynyl groups containing one or more alkenyl groups may be provided or alkenyl groups containing one or more alkynyl groups may be provided

When X contains one or more double bonds, preferably at least one, more preferably each, is in *cis* configuration.

35

Y


As discussed above Y is selected from at least one of S, Se, SO₂, SO, O, CH₂. When Y is CH₂, the chain X-Y-Z contains an even number of atoms. It will be understood that the chain length of X-Y-Z is the longest chain of directly bonded atoms within moiety X-Y-Z. It will be understood that a chain does not include atoms of cyclic substituents or substituents of a terminal carbon.

In one preferred aspect Y is selected from S, Se, SO₂, SO, and O.

10 In one preferred aspect Y is selected from S and Se.


in a highly preferred aspect Y is S.

15 In a further highly preferred aspect the compound of the present invention is of the formula



wherein groups X and Z are selected independently of each other.

20 In a further highly preferred aspect the compound of the present invention is of the formula



wherein groups X and Z are selected independently of each other.

Z

As discussed above Z is an optional hydrocarbyl group.

In one preferred aspect Z is an alkyl group.

5

In one preferred aspect Z is a C₁-C₁₀, preferably C₁-C₆, preferably C₁-C₃ alkyl group. Preferably Z is -CH₂-.

YZ

10

In one aspect Y and Z together may be formed by a unit which may repeat within the YZ moiety.

15

Preferably Y-Z together represent the group [Y¹-CH₂]_n, wherein Y¹ is selected from S, Se, SO₂, SO, O, CH₂, wherein when Y¹ is CH₂, the chain X-Y-Z contains an even number of atoms, and wherein n is an integer from 1 to 20


In this aspect preferably Y¹ is selected from S, Se, SO₂, SO, and O. More preferably Y¹ is selected from S and Se. Yet more preferably Y¹ is S.

20

Preferably n is from 1 to 10, more preferably from 1 to 5, more preferably 1, 2 or 3. In one highly preferred aspect n is 1.

In one aspect the compound is of the formula

25




wherein p is at least 1, such as 1 to 10000, 1 to 1000, 1 to 100, 1 to 50, 1 to 20, 1 to 10, preferably 1 to 5, preferably 1, 2 or 3, and wherein each W, X, Y and Z is selected independently of each other.

30

Examples of suitable compounds from which the polar head group may be derived for given values of p are as follows


p	
1	glycerols alcohols alkoxy compounds lysophospholipids monoacylglycerols gangliosides sphingomyelins cerebroside
2	phosphatidylcholines (PC) phosphatidylethanolamines (PE), phosphatidylserines (PS) phosphatidylinositols (PI) diacylglycerols Phosphatidic acids glycerocarbohydrates phosphatidylglycerols
3	triacylglycerols
1 or more	polyalcohols

In one aspect the compound is of the formula




wherein p is 1 to 10, preferably 1 to 5, preferably 1, 2 or 3, and wherein each W, X, Y and Z is selected independently of each other.

In one aspect the compound is of the formula




10 In one aspect the compound is of the formula



Preferably the compound comprises at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X-Y-Z-.


5

In one preferred aspect the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.


10 In one preferred aspect the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.

15 In one aspect the compound comprises at least three non-polar moieties wherein each is independently selected from non-polar moieties of the formula X-Y-Z-.


In one preferred aspect the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.

20


In one preferred aspect the compound is of the formula



wherein each W, X, Y and Z is selected independently of each other.


Further highly preferred aspects of the present invention are described below. The present invention may provide

- a compound is of the formula




wherein Y^2 and Y^3 are independently S or Se, and X^2 and X^3 are independently selected from unsubstituted C_{10} - C_{18} alkyl, unsubstituted C_{10} - C_{18} alkenyl and unsubstituted C_{10} - C_{18} alkynyl.

- a compound is of the formula




X^2 and X^3 are independently selected from unsubstituted C_{10} - C_{18} alkyl, unsubstituted C_{10} - C_{18} alkenyl and unsubstituted C_{10} - C_{18} alkynyl.

- a compound is of the formula




X^2 and X^3 are independently selected from unsubstituted C_{14} alkyl, unsubstituted C_{14} alkenyl and unsubstituted C_{14} alkynyl.

- 5 • a compound is of the formula




X^2 and X^3 are independently selected from $CH_3(CH_2)_{13}-$, $CH_3(CH_2)_6CH=CH(CH_2)_5-$, and $CH_3CH_2C\equiv C(CH_2)_{10}-$.

- 10 • a compound is of the formula




X^2 and X^3 are both $CH_3(CH_2)_{13}-$.

- a compound is of the formula



X^2 and X^3 are both $\text{CH}_3(\text{CH}_2)_6\text{CH}=\text{CH}(\text{CH}_2)_5^-$.


- a compound is of the formula



5


X^2 and X^3 are both $\text{CH}_3\text{CH}_2\text{C}\equiv\text{C}(\text{CH}_2)_{10}^-$.

- a compound is of the formula




- 10 X^2 and X^3 are both $\text{CH}_3(\text{CH}_2)_{13}^-$, wherein the PHG is derived from the polar head group of a phosphatidylcholine (PC), or a phosphatidylethanolamine (PE).

- a compound is of the formula



X^2 and X^3 are both $\text{CH}_3(\text{CH}_2)_6\text{CH}=\text{CH}(\text{CH}_2)_5-$, wherein PHG is derived from the polar head group of a phosphatidylcholine (PC), or a phosphatidylethanolamine (PE).

- 5 • a compound is of the formula



X^2 and X^3 are both $\text{CH}_3\text{CH}_2\text{C}\equiv\text{C}(\text{CH}_2)_{10}-$, wherein PHG is derived from the polar head group of a phosphatidylcholine (PC), or a phosphatidylethanolamine (PE).

10 Further Aspects

The compounds of the present invention may be combined with a liposome or formulated into micellar form to assist in administration.

- 15 In a further aspect the present compound maybe formulated in a cochleate delivery vehicles. Cochleate delivery vehicles represent a new technology platform for oral delivery of drugs. Cochleates are stable phospholipid-cation precipitates composed of simple, naturally occurring materials, for example, phosphatidylserine and calcium. Cochleates are a potential nanosized system that can encapsulate hydrophobic,
20 amphiphilic, negatively or positively charged moieties.

In one aspect the compound of the present invention is an isolated form or purified form. For example, the compound may be in a form or at a purity other than that found in a biological system such as *in vivo*.

The compounds of the present invention may be formulated to provide a pharmaceutical composition comprising a compound of the invention optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

5

Pharmaceutical Composition

The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the agent of the present invention and a pharmaceutically acceptable carrier, diluent or excipients (including combinations thereof).

This is a composition that comprises or consists of a therapeutically effective amount of a pharmaceutically active agent. It preferably includes a pharmaceutically acceptable carrier, diluent or excipients (including combinations thereof). Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit.¹ 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

This pharmaceutical composition will desirably be provided in a sterile form. It may be provided in unit dosage form and will generally be provided in a sealed container. A plurality of unit dosage forms may be provided.

Pharmaceutical compositions within the scope of the present invention may include one or more of the following: preserving agents, solubilising agents, stabilising agents, wetting agents, emulsifiers, sweeteners, colourants, flavouring agents, odourants, salts compounds of the present invention may themselves be provided in the form of a pharmaceutically acceptable salt), buffers, coating agents, antioxidants, suspending agents, adjuvants, excipients and diluents. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid.

35

They may also contain other therapeutically active agents in addition to compounds of the present invention. Where two or more therapeutic agents are used they may be administered separately (e.g. at different times and/or via different routes) and therefore do not always need to be present in a single composition. Thus combination therapy is within
5 the scope of the present invention.

Route Of Administration

A pharmaceutical composition within the scope of the present invention may be adapted for
10 administration by any appropriate route. For example, it may be administered by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) routes. Such a composition may be prepared by any method known in the art of pharmacy, for example by admixing one or more active ingredients with a suitable carrier.

15 Different drug delivery systems can be used to administer pharmaceutical compositions of the present invention, depending upon the desired route of administration. Drug delivery systems are described, for example, by Langer (Science 249:1527 – 1533 (1991)) and by Illum and Davis (Current Opinions in Biotechnology 2: 254 – 259 (1991)). Different routes of
20 administration for drug delivery will now be considered in greater detail:

The agents of the present invention may be administered alone but will generally be administered as a pharmaceutical composition – e.g. when the agent is in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the
25 intended route of administration and standard pharmaceutical practice.

For example, the agent can be administered (e.g. orally or topically) in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or
30 controlled-release applications.

The tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycolate,
35 croscarmellose sodium and certain complex silicates, and granulation binders such as

polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

- 5 Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the agent may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents such as water,
10 ethanol, propylene glycol and glycerin, and combinations thereof.

The routes for administration (delivery) include, but are not limited to, one or more of: oral (e.g. as a tablet, capsule, or as an ingestible solution), topical, mucosal (e.g. as a nasal spray or aerosol for inhalation), nasal, parenteral (e.g. by an injectable form),
15 gastrointestinal, intraspinal, intraperitoneal, intramuscular, intravenous, intrauterine, intraocular, intradermal, intracranial, intratracheal, intravaginal, intracerebroventricular, intracerebral, subcutaneous, ophthalmic (including intravitreal or intracameral), transdermal, rectal, buccal, *via* the penis, vaginal, epidural, sublingual.

- 20 It is to be understood that not all of the agent need be administered by the same route. Likewise, if the composition comprises more than one active component, then those components may be administered by different routes.

If the agent of the present invention is administered parenterally, then examples of such
25 administration include one or more of: intravenously, intra-arterially, intraperitoneally, intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.

30 (I) Oral Administration

Pharmaceutical compositions adapted for oral administration may be provided as capsules or tablets; as powders or granules; as solutions, syrups or suspensions (in aqueous or non-aqueous liquids); as edible foams or whips; or as emulsions. Tablets or hard gelatine
35 capsules may comprise lactose, maize starch or derivatives thereof, stearic acid or salts

thereof. Soft gelatine capsules may comprise vegetable oils, waxes, fats, semi-solid, or liquid polyols etc. Solutions and syrups may comprise water, polyols and sugars. For the preparation of suspensions oils (e.g. vegetable oils) may be used to provide oil-in-water or water-in-oil suspensions. An active agent intended for oral administration may be coated
5 with or admixed with a material that delays disintegration and/or absorption of the active agent in the gastrointestinal tract (e.g. glyceryl monostearate or glyceryl distearate may be used). Thus the sustained release of an active agent may be achieved over many hours and, if necessary, the active agent can be protected from being degraded within the stomach. Pharmaceutical compositions for oral administration may be formulated to
10 facilitate release of an active agent at a particular gastrointestinal location due to specific pH or enzymatic conditions.

(li) Transdermal Administration

15 Pharmaceutical compositions adapted for transdermal administration may be provided as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis. (Iontophoresis is described in *Pharmaceutical Research*,
3(6):318 (1986).)

20

(lii) Topical Administration

Alternatively, the agent of the present invention can be administered in the form of a suppository or pessary, or it may be applied topically in the form of a gel, hydrogel, lotion,
25 solution, cream, ointment or dusting powder. The agent of the present invention may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes. They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as
30 solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin, the agent of the present invention can be formulated
35 as a suitable ointment containing the active compound suspended or dissolved in, for

example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, it can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following:

5 mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

(Iv) Rectal Administration

10 Pharmaceutical compositions adapted for rectal administration may be provided as suppositories or enemas.

(V) Nasal Administration

15 Pharmaceutical compositions adapted for nasal administration may use solid carriers, e.g. powders (preferably having a particle size in the range of 20 to 500 microns). Powders can be administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nose from a container of powder held close to the nose. Compositions adapted for nasal administration may alternatively use liquid carriers, e.g. nasal sprays or nasal drops. These

20 may comprise aqueous or oil solutions of the active ingredient.

Compositions for administration by inhalation may be supplied in specially adapted devices – e.g. in pressurised aerosols, nebulizers or insufflators. These devices can be constructed so as to provide predetermined dosages of the active ingredient.

25

(Vi) Vaginal Administration

Pharmaceutical compositions adapted for vaginal administration may be provided as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

30

(Vii) Parenteral Administration

If the agent of the present invention is administered parenterally, then examples of such administration include one or more of: intravenously, intra-arterially, intraperitoneally,

35 intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially,

intramuscularly or subcutaneously administering the agent; and/or by using infusion techniques.

For parenteral administration, the agent is best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

Transdermal

"Transdermal" refers to the delivery of a compound by passage through the skin and into the blood stream.

Transmucosal

"Transmucosal" refers to delivery of a compound by passage of the compound through the mucosal tissue and into the blood stream.

Transurethral Or Intraurethral

"Transurethral" or "intraurethral" refers to delivery of a drug into the urethra, such that the drug contacts and passes through the wall of the urethra and enters into the blood stream.

Penetration Enhancement Or Permeation Enhancement

"Penetration enhancement" or "permeation enhancement" refers to an increase in the permeability of the skin or mucosal tissue to a selected pharmacologically active compound such that the rate at which the compound permeates through the skin or mucosal tissue is increased.

Penetration enhancers may include, for example, dimethylsulfoxide (DMSO), dimethylformamide (DMF), N,N-dimethylacetamide (DMA), dodecylmethylsulfoxide (CIOMSO),

polyethyleneglycol monolaurate (PEGML), glycerol monolaurate, lecithin, 1-substituted azacycloheptanones, particularly 1-N-dodecylcyclazacycloheptanones (available under the trademark Azone TM from Nelson Research & Development Co., Irvine, CA), alcohols and the like.

5

Carriers Or Vehicles

"Carriers" or "vehicles" refers to carrier materials suitable for compound administration and include any such material known in the art such as, for example, any liquid, gel, solvent, liquid diluent, solubilizer, or the like, which is non-toxic and which does not interact with any components of the composition in a deleterious manner.

Examples of pharmaceutically acceptable carriers include, for example, water, salt solutions, alcohol, silicone, waxes, petroleum jelly, vegetable oils, polyethylene glycols, propylene glycol, sugars, gelatin, lactose, amylose, magnesium stearate, talc, surfactants, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, petroethral fatty acid esters, hydroxymethyl-cellulose, polyvinylpyrrolidone, and the like.

20 Epidermal Drug Delivery (Transfersomes)

Transfersomes ("carrying bodies") are complex, most often vesicular, bi- or multi-component aggregates capable of crossing barriers and of transferring material between the application and the destination sites. Transfersomes are sold by IDEA Corporation, Munich, Germany, and TRANSFERSOME is a trade mark of that company. Transfersome transdermal drug delivery technology may be used for controllable and non-invasive delivery of a wide variety of large molecules as well as for the improved delivery of small molecules, including the metabolic enzyme antagonists and/or drugs of the present invention.

30

Transfersomes may be optimised to attain extremely flexible and self-regulating membranes. They are therefore deformable and consequently can cross microporous barriers efficiently, even when the available passages are much smaller than the average aggregate size. Transfersome formulations are typically composed of natural amphipatic compounds suspended in a water-based solution, optionally containing biocompatible

35

surfactants. Vesicular Transfersomes consist of a lipid bilayer surrounding an aqueous core and further contain at least one component, capable of softening the membrane. The bilayer of a Transfersome is therefore more flexible than a liposome membrane, even metastable. Transfersome vesicles consequently change their shape easily by
5 adjusting locally to ambient stress.

Skin is one of the best biological barriers. Its outermost part, the horny layer, reaches less than 10% into the depth of the skin but contributes over 80% to the skin permeability barrier. This body protecting layer consists of overlapping, flaccid corneocytes, organized
10 in columnar clusters, sealed with multilamellar lipid sheets that are covalently attached to the cell membranes and very tightly packed. Generally, the average number of and the degree of order in the intercellular lipid lamellae increases toward the skin surface. This is accompanied by a continuous, but nonlinear, decrease in local water content near the surface. Notwithstanding this, the peak skin barrier is located in the inner half of the
15 horny layer, where the intercellular lipid seals are already formed, but not yet compromised by the skin cells detachment.

Passage of transfersome aggregates across the skin is a function of vesicle membrane flexibility, hydrophilicity, and the ability to retain vesicle integrity, while the aggregate
20 undergoes a significant change in shape. When a suspension of Transfersome vesicles is placed on the surface of the skin, water evaporates from the relatively arid skin surface and the vesicles start to dry out. Due to the strong polarity of major Transfersome ingredients, the large number of hydrophilic groups on the membrane, assisted by the softness of the membrane, the vesicles are attracted to the areas of higher water content
25 in the narrow gaps between adjoining cells in the skin barrier, enabling skin penetration of the vehicle. This, together with the vesicle's extreme ability to deform, enables Transfersome aggregates to open, temporarily, the tiny "cracks" through which water normally evaporates out of the skin. Channels between the skin cells, two orders of magnitude wider than the original micropores, are thus created. Such newly activated
30 passages can accommodate sufficiently deformable vesicles, which maintain their integrity but change their shape to fit the channel. Along the resulting "virtual pathways", or "virtual channels" in the horny layer, Transfersomes reach regions of high water content in the deeper skin layers. There, the vesicles (re)distribute. Since Transfersomes are too large to enter the blood vessels locally, they bypass the capillary bed and get to
35 subcutaneous tissue, where they accumulate.

Although small molecules that have crossed the horny layer of the skin (stratum corneum) are normally cleared from the skin through the blood circulation, delivery of drugs by means of Transfersome vesicles allows accumulation of drug deep under the skin. Due to their large size, the vesicles are cleared slowly from the skin and associated
 5 drugs can accumulate at the site. Transfersome mediated administration of weight drugs, consequently, tends to shift the drug distribution towards the deep tissue under the application site.

Blood Brain Barrier (BBB)

10

Pharmaceutical compositions may be designed to pass across the blood brain barrier (BBB). For example, a carrier such as a fatty acid, inositol or cholesterol may be selected that is able to penetrate the BBB. The carrier may be a substance that enters the brain through a specific transport system in brain endothelial cells, such as insulin-like growth
 15 factor I or II. The carrier may be coupled to the active agent or may contain/be in admixture with the active agent. Liposomes can be used to cross the BBB. WO91/04014 describes a liposome delivery system in which an active agent can be encapsulated/embedded and in which molecules that are normally transported across the BBB (e.g. insulin or insulin-like growth factor I or II) are present on the liposome
 20 outer surface. Liposome delivery systems are also discussed in US Patent No. 4704355.

Polymer Delivery / Therapeutics

The agents may further be delivered attached to polymers. Polymer based therapeutics
 25 have been proposed to be effective delivery systems, and generally comprise one or more agents to be delivered attached to a polymeric molecule, which acts as a carrier. The agents are thus disposed on the polymer backbone, and are carried into the target cell together with the polymer.

30 The agents may be coupled, fused, mixed, combined, or otherwise joined to a polymer. The coupling, etc between the agent and the polymer may be permanent or transient, and may involve covalent or non-covalent interactions (including ionic interactions, hydrophobic forces, Van der Waals interactions, etc). The exact mode of coupling is not important, so long as the agent is taken into a target cell substantially together with the
 35 polymer. For simplicity, the entity comprising the agent attached to the polymer carrier is

referred to here as a "polymer-agent conjugate".

Any suitable polymer, for example, a natural or synthetic polymer, may be used, preferably the carrier polymer is a synthetic polymer such as PEG. More preferably, the carrier polymer is a biologically inert molecule. Particular examples of polymers include
5 polyethylene glycol (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers, polyamidoamine (PAMAM) dendrimers, HEMA, linear polyamidoamine polymers etc.

Any suitable linker for attaching the agent to the polymer may be used. Preferably, the linker is a biodegradable linker. Use of biodegradable linkers enables controlled release
10 of the agent on exposure to the extracellular or intracellular environment. High molecular weight macromolecules are unable to diffuse passively into cells, and are instead engulfed as membrane-encircled vesicles. Once inside the vesicle, intracellular enzymes may act on the polymer-agent conjugate to effect release of the agent. Controlled intracellular release circumvents the toxic side effects associated with many drugs.

Furthermore, agents may be conjugated, attached etc by methods known in the art to any suitable polymer, and delivered. The agents may in particular comprise any of the molecules referred to as "second agents", such as polypeptides, nucleic acids, macromolecules, etc, as described in the section below. In particular, the agent may
20 comprise a pro-drug as described elsewhere.

The ability to choose the starting polymer enables the engineering of polymer-agent conjugates for desirable properties. The molecular weight of the polymer (and thus the polymer-agent conjugate), as well as its charge and hydrophobicity properties, may be
25 precisely tailored. Advantages of using polymer-agent conjugates include economy of manufacture, stability (longer shelf life) and reduction of immunogenicity and side effects. Furthermore, polymer-agent conjugates are especially useful for the targeting of tumour cells because of the enhanced permeability and retention (EPR) effect, in which growing tumours are more 'leaky' to circulating macromolecules and large particules, allowing
30 them easy access to the interior of the tumour. Increased accumulation and low toxicity (typically 10-20% of the toxicity of the free agent) are also observed. Use of hyperbranched dendrimers, for example, PAMAM dendrimers, is particularly advantageous in that they enable monodisperse compositions to be made and also flexibility of attachment sites (within the interior or the exterior of the dendrimer). The pH
35 responsiveness of polymer-agent conjugates, for example, those conjugated to

polyamindoamine polymers, may be tailored for particular intracellular environments. This enables the drug to be released only when the polymer therapeutic encounters a particular pH or range of pH, i.e., within a particular intracellular compartment. The polymer agent conjugates may further comprise a targeting means, such as an immunoglobulin or antibody, which directs the polymer-agent conjugate to certain tissues, organs or cells comprising a target, for example, a particular antigen. Other targeting means are described elsewhere in this document, and are also known in the art.

Particular examples of polymer-agent conjugates include "Smancs", comprising a conjugate of styrene-co-maleic anhydride and the antitumour protein neocarzinostatin, and a conjugate of PEG (poly-ethylene glycol) with L-asparaginase for treatment of leukaemia; PK1 (a conjugate of a HPMA copolymer with the anticancer drug doxorubicin); PK2 (similar to PK1, but furthermore including a galactose group for targeting primary and secondary liver cancer); a conjugate of HPMA copolymer with the anticancer agent captothecin; a conjugate of HPMA copolymer with the anticancer agent paclitaxel; HPMA copolymer-platinate, etc. Any of these polymer-agent conjugates are suitable for co-loading into the transgenic cells of the present invention.

Dose Levels

Typically, a physician will determine the actual dosage which will be most suitable for an individual subject. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. The agent and/or the pharmaceutical composition of the present invention may be administered in accordance with a regimen of from 1 to 10 times per day, such as once or twice per day.

For oral and parenteral administration to human patients, the daily dosage level of the agent may be in single or divided doses.

Depending upon the need, the agent may be administered at a dose of from 0.01 to 30

mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight. Naturally, the dosages mentioned herein are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

5

Therapeutically Effective Amount

"Therapeutically effective amount" refers to the amount of the therapeutic agent which is effective to achieve its intended purpose. While individual patient needs may vary, determination of optimal ranges for effective amounts of each nitric oxide adduct is within the skill of the art. Generally the dosage regimen for treating a condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the dysfunction, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound used, whether a drug delivery system is used, and whether the compound is administered as part of a drug combination and can be adjusted by one skilled in the art. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from the preferred dosage regimen set forth herein.

10
15
20

Individual

As used herein, the term "individual" refers to vertebrates, particularly members of the mammalian species. The term includes but is not limited to domestic animals, sports animals, primates and humans.

25

PHARMACEUTICAL COMBINATIONS

In general, the agent may be used in combination with one or more other pharmaceutically active agents. The other agent is sometimes referred to as being an auxiliary agent.

30

Patient

"Patient" refers to animals, preferably mammals, more preferably humans.

35

Pharmaceutically Acceptable Salt

The agent may be in the form of – and/or may be administered as - a pharmaceutically acceptable salt – such as an acid addition salt or a base salt – or a solvate thereof, including a hydrate thereof. For a review on suitable salts see Berge et al, J. Pharm. Sci., 1977, 66, 1-19.

Typically, a pharmaceutically acceptable salt may be readily prepared by using a desired acid or base, as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate salts.

Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.

Disease States

In one aspect the present invention provides use of a compound of the invention in the manufacture of a medicament for the treatment and/or prevention of a condition selected from syndrome X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis.

In one aspect the present invention provides use of a compound of the invention in the manufacture of a medicament for lowering concentration of cholesterol and triglycerides in the blood of mammals and/or inhibiting the oxidative modification of low density lipoprotein.

In one aspect the present invention provides a method for producing weight loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising

administering thereto an effective amount of a compound of the invention.

Further description of these and other diseases is provided below.

5 OBESITY, AND RELATED DISEASES

Obesity is a chronic disease that is highly prevalent in modern society and is associated not only with a social stigma, but also with decreased life span and numerous medical problems, including adverse psychological development, reproductive disorders such as
10 polycystic ovarian disease, dermatological disorders such as infections, varicose veins, Acanthosis nigricans, and eczema, exercise intolerance, diabetes mellitus, insulin resistance, hypertension, hypercholesterolemia, cholelithiasis, osteoarthritis, orthopedic injury, thromboembolic disease, cancer, and coronary heart disease.

15 The present invention therefore aims to provide a treatment regimen that is useful in returning the body weight of obese subjects toward a normal, ideal body weight.

The present invention therefore aims to provide a therapy for obesity that results in maintenance of the lowered body weight for an extended period of time. Further, The
20 present invention therefore aims to reduce or inhibit the weight gain normally induced by fat rich diets.

The present invention therefore aims to prevent obesity and, once treatment has begun, to arrest progression or prevent the onset of diseases that are the consequence of, or
25 secondary to, the obesity, such as hypertension and fatty liver.

The obesity herein may be due to any cause, whether genetic or environmental. Examples of disorders that may result in obesity or be the cause of obesity include overeating and bulimia, polycystic ovarian disease, craniopharyngioma, the Prader-Willi
30 Syndrome, Frohlich's syndrome, Type II diabetics, GH-deficient subjects, normal variant short stature, Turner's syndrome, and other pathological conditions showing reduced metabolic activity.

The present invention therefore aims to provide a treatment regimen that is useful in
35 lowering the blood pressure.

Further, The present invention therefore aims to provide a treatment regimen that is useful in lowering the concentration of triacylglycerols in the liver. It is anticipated that such a regimen will provide an inhibiting effect on the development of a fatty liver condition, and also be suited as a method for the treatment of the manifested disease.

The compounds of the present invention activate the oxidation, and also reduce the concentration of triglycerides in the liver.

10 The term "metabolic syndrome" is used to describe a multimetabolic syndrome which is inter alia characterised by hyperinsulinemia, insulin resistance, obesity, glucose intolerance, Type 2 diabetes mellitus, dyslipidemia or hypertension.

As indicated above it is anticipated that the compounds of the present invention will provide a positive effect on all the conditions mentioned above, i. e. by regulating both the glucose and lipid homeostasis, and thus it is anticipated that the compounds of the present invention will be suitable agents for the regulation of the above defined metabolic disease (sometimes called syndrome X).

20 DIABETES

There are two major forms of diabetes mellitus. One is type I diabetes, which is also known as insulin-dependent diabetes mellitus (IDDM), and the other is type II diabetes, which is also known as noninsulin-dependent diabetes mellitus (NIDDM). Most patients with IDDM have a common pathological picture ; the nearly total disappearance of insulin-producing pancreatic beta cells which results in hyperglycemia.

Considerable evidence has been accumulated showing that most IDDM is the consequence of progressive beta-cell destruction during an asymptomatic period often extending over many years. The prediabetic period can be recognised by the detection of circulating islet-cell autoantibodies and insulin autoantibodies.

There is a need for a compound which would be nontoxic and have no side effects but which would prevent clinical IDDM and NIDDM.

Type I diabetes : severe diabetes mellitus, usually of abrupt onset prior to maturity, characterised by low plasma insulin levels, polydipsia, polyuria, increased appetite, weight loss and episodic ketoacidosis ; also referred to as IDDM.

- 5 Type II diabetes : an often mild form of diabetes mellitus, often of gradual onset, usually in adults; characterised by normal to high absolute plasma insulin levels which are relatively low in relation to plasma glucose levels ; also referred to as NIDDM.

10 Type I and II diabetes are in accordance with an etiologic classification considered as primary diabetes respectively.

15 Secondary diabetes comprises pancreatic, extrapancreatic/ endocrine or drug-induced diabetes. Further, some types of diabetes are classified as exceptional forms. These include lipoatrophic, myatonic diabetes, and a type of diabetes caused by disturbance of insulin receptors.

20 Considering the high prevalence of diabetes in our society and the serious consequences associated therewith as discussed above, any therapeutic drug potentially useful for the treatment and prevention of this disease could have a profound beneficial effect on their health. There is a need in the art for a drug that will reduce the concentration of glucose in the blood of diabetic subjects without significant adverse side effects.

25 The present invention therefore aims to provide a treatment regimen that is useful in lowering the blood glucose and to treat a diabetic condition.

The present invention therefore aims to provide a treatment regimen that is useful in lowering the concentration of insulin in the blood, and to increase the effect of the remaining insulin.

30

STENOSIS

Many pathological conditions have been found to be associated with smooth muscle cell proliferation. Such conditions include restenosis, arteriosclerosis, coronary heart disease,

thrombosis, myocardial infarction, stroke, smooth muscle neoplasms such as leiomyoma and leiomyosarcoma of the bowel and uterus and uterine fibroid or fibroma.

Over half a million interventional intravascular procedures are performed each year.

- 5 While such invasive procedures continue to improve over time, as many as 30-50% of the procedures performed each year fail as a result of restenosis, i. e. the formation of secondary stenosis. The reduction of restenosis is, therefore, often cited as the most critical factor in increasing the success realised in the treatment of cardiovascular disease through the use of interventional intravascular procedures, such as angioplasty, 10 atherectomy, and procedures utilising stents and laser technology.

- In balloon angioplasty, e. g. Percutaneous Transluminal Coronary Angioplasty (PTCA), a small incision is made to an artery in the patient's leg or arm and a long hollow tube, called a guide catheter, is inserted into the artery. A thick guide wire and deflated balloon 15 catheter are then inserted into the guide catheter and are carefully advanced through the patient's blood vessels using x-ray visualization. The deflated balloon is advanced until it reaches the site of the luminal narrowing, at which point the physician inflates the balloon one or more times to a pressure of about 4-6 atm for about 60 sec. When inflated, the balloon cracks and fractures the plaque and stretches the muscle fibre in the artery wall 20 beyond its ability to recoil completely. Although no plaque is removed in this procedure, the fracturing of the plaque and the stretching of the arterial wall increase the vessel lumen, thereby allowing for increased blood flow.

- The restenosis that accompanies such procedures is characterised by platelet 25 aggregation and adhesion, smooth muscle cell proliferation, narrowing of the vessel lumen, restricted vasodilatation, and an increase in blood pressure. Smooth muscle cells in the intimal layer of the artery have been reported to enter the growth cycle within about 2-3 days of these procedures and to proliferate for several days thereafter (intimal hyperplasia).

- 30 Compounds that reportedly suppress smooth muscle proliferation in vitro may have undesirable pharmacological side effects when used in vivo. Heparin is an example of one such compound, which reportedly inhibits smooth muscle cell proliferation in vitro but when used in vivo has the potential adverse side effect of inhibiting coagulation.

As is apparent from the foregoing, many problems remain to be solved in the use of inhibitory drugs to effectively treat smooth muscle cell mobilisation and proliferation. It would be highly advantageous to develop new compositions or methods for inhibiting stenosis, restenosis or related disorders due to proliferation and mobilisation of vascular smooth muscle cells following, for example, traumatic injury to vessels rendered during vascular surgery.

It is anticipated that the compounds in accordance with the present invention will be effectively it the treatment of these diseases.

10

In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

25

In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune deficiency, including infection with human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and...

35

periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

In addition, or in the alternative, the composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididymo-orchitis, infertility, orchidal trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fundus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune

and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial,

5 Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute

10 sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillain-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune

15 and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier,

20 or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or

25 artificial skin tissue.

Treatment

This includes any therapeutic application that can benefit a human or non-human animal.

30 The treatment of mammals is particularly preferred. Both human and veterinary treatments are within the scope of the present invention.

Treatment may be in respect of an existing condition or it may be prophylactic. It may be of an adult, a juvenile, an infant, a foetus, or a part of any of the aforesaid (e.g. an organ,

35 tissue, cell, or nucleic acid molecule).

An active agent for use in treatment can be administered via any appropriate route and at any appropriate dosage. Dosages can vary between wide limits, depending upon the nature of the treatment, the age and condition of the individual to be treated, etc. and a physician will ultimately determine appropriate dosages to be used. However, without being bound by any particular dosages, a daily dosage of a compound of the present invention of from 1 μ g to 1mg/kg body weight may be suitable. The dosage may be repeated as often as appropriate. If side effects develop, the amount and/or frequency of the dosage can be reduced, in accordance with good clinical practice.

10

Polymorphic Form(S)/Asymmetric Carbon(S)

The agent of the present invention may exist in polymorphic form.

15 The agent of the present invention may contain one or more asymmetric carbon atoms and therefore exists in two or more stereoisomeric forms. Where an agent contains an alkenyl or alkenylene group, cis (E) and trans (Z) isomerism may also occur. The present invention includes the individual stereoisomers of the agent and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.

20

Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of the agent or a suitable salt or derivative thereof. An individual enantiomer of a compound of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.

30 Isotopic Variations

The present invention also includes all suitable isotopic variations of the agent or a pharmaceutically acceptable salt thereof. An isotopic variation of an agent of the present invention or a pharmaceutically acceptable salt thereof is defined as one in which at least one atom is replaced by an atom having the same atomic number but an atomic mass

35

different from the atomic mass usually found in nature. Examples of isotopes that can be incorporated into the agent and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulphur, fluorine and chlorine such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F and ^{36}Cl , respectively.

5 Certain isotopic variations of the agent and pharmaceutically acceptable salts thereof, for example, those in which a radioactive isotope such as ^3H or ^{14}C is incorporated, are useful in drug and/or substrate tissue distribution studies. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with isotopes such as deuterium, i.e., ^2H , may afford
10 certain therapeutic advantages resulting from greater metabolic stability, for example, increased *in vivo* half-life or reduced dosage requirements and hence may be preferred in some circumstances. Isotopic variations of the agent of the present invention and pharmaceutically acceptable salts thereof of this invention can generally be prepared by conventional procedures using appropriate isotopic variations of suitable reagents.

15 Pro-Drug

It will be appreciated by those skilled in the art that the agent of the present invention may be derived from a prodrug. Examples of prodrugs include entities that have certain
20 protected group(s) and which may not possess pharmacological activity as such, but may, in certain instances, be administered (such as orally or parenterally) and thereafter metabolised in the body to form the agent of the present invention which are pharmacologically active.

25 Pro-Moiety

It will be further appreciated that certain moieties known as "pro-moieties", for example as described in "Design of Prodrugs" by H. Bundgaard, Elsevier, 1985 (the disclosure of which is hereby incorporated by reference), may be placed on appropriate functionalities
30 of the agents. Such prodrugs are also included within the scope of the invention.

Derivative

The term "derivative" or "derivatised" as used herein includes chemical modification of an
35 agent. Illustrative of such chemical modifications would be replacement of hydrogen by a

halo group, an alkyl group, an acyl group or an amino group.

Chemical Modification

- 5 In one embodiment of the present invention, the agent may be a chemically modified agent.

The chemical modification of an agent of the present invention may either enhance or reduce hydrogen bonding interaction, charge interaction, hydrophobic interaction, Van
10 Der Waals interaction or dipole interaction between the agent and the target.

In one aspect, the identified agent may act as a model (for example, a template) for the development of other compounds.

- 15 The present invention will now be described in further detail in the following examples.


EXAMPLES

SYNTHESIS OF THE FATTY ACIDS

20

Fatty acid derivatives for use in accordance with the present invention may be synthesised in accordance with the teaching of WO01/68502.

The strategy for synthesizing fatty acids 3 and 4 is given in Scheme 1. Firstly, the
25 condensation of thioacetic acid and tetradecyl bromide in the presence of sodium methoxide yields, after acidification, TTA as a colourless solid in 82% yield.



Scheme 1


(a) NaOMe, MeOH, r.t., 2 d; then H^+ , 82%; (b) PPh_3 , AcOH, reflux, 6 d, 98%; (c) NaH, DMSO, then octaldehyde, 0°C , 54%; (d) PBr_3 , pyridine, Et_2O , 70%; (e) thioacetic acid, NaOMe, MeOH then **8**, 96%.

The synthesis of *cis*-alkene analogue **4** proceeds with a Wittig reaction between phosphonium salt **6** and 1-octanal to afford *cis*-alkene alcohol **7** (59% yield).⁷

- 5 Bromination of the alcohol and subsequent reaction with the disodium salt of thioacetic acid yielded the desired fatty acid dTTA **4** (67% for the 2 steps).

Because of uncertainty of the *cis/trans* selectivity of the Wittig reaction a more *cis*-selective approach was utilized (Scheme 2). Thus the acetate **9** was hydrolysed with *p*-


- 10 TsOH, the resultant primary alcohol THP-protected and the bromide transformed into an iodide *via* a Finkelstein halogen exchange reaction thereby affording **10** in a good 70% yield for the 3 steps. Iodide **10** was then reacted with the *in situ* generated alkynyl lithiate of **11** giving the protected alkynyl alcohol **12** (76% yield). At this stage the alkene was generated by the *cis*-selective Lindlar hydrogenation, which proceeded smoothly and in
- 15 good yield (93%). GC-MS analysis showed homogeneity of the *cis* moiety. The protected alcohol was transformed in one step to the bromide **8** which was subsequently treated with thioacetic acid in the presence of base to afford the desired fatty acid **4** (dTTA) in 74% yield.(2 steps).



Scheme 2

(a) *p*TsOH, MeOH, Δ ; (b) DHP, PPTS, CH_2Cl_2 , r.t.; (c) NaI, acetone, Δ , > 70% for 3 steps; (d) *n*-BuLi, THF/HMPA, 0°C , then 2-(3-iodopentoxy)tetrahydropyran, 76%; (e) Lindlar catalyst, H_2 , quinoline, hexanes, 93%; (f) PPh_3Br_2 , PPh_3 , CH_2Cl_2 , 0°C , 86%; (g) thioacetic acid, NaOMe, MeOH, then 8, >85%

Alkyne analogue 5 was synthesized in a similar manner as above. THP-protection of 10-bromodecan-1-ol yielded 14 (74% yield) (Scheme 3).⁸ The resultant bromide 14 was then treated with lithium acetylide giving terminal alkyne 15 in 65% yield.⁹ Deprotonation of the alkyne with *n*-butyl lithium allowed by treatment of the resultant lithiate with ethyl iodide in the presence of HMPA afforded the alkylated alkyne 16.⁹ The synthesis was completed in a manner analogous to the synthesis of 4 giving the desired TTA 5 in an overall 35% yield.






Scheme 3


(a) DHP, PPTS, CH_2Cl_2 , r.t., 74%; (b) lithium acetylide, DMSO, 65%; (c) *n*-BuLi, THF/HMPA, EtI, 0°C ; (d) PPh_3Br_2 , PPh_3 , CH_2Cl_2 , 87% for 2 steps; (e) thioacetic acid, NaOMe, MeOH then 17, 86%

2.2 SYNTHESIS OF PHOSPHOLIPID DERIVATIVES

The synthesis of phosphatidylcholine (PC) derivative 1,2-ditetradecylthioacetoyl-*sn*-glycero-3-phosphocholine (TTA-PC, **18**) is shown in Scheme 4. The analogues dTTA-PC **19** and tTTA-PC **20** were synthesized in analogous manner.

TTA-PC **18**dTTA-PC **19**tTTA-PC **20**

The acylation of *sn*-glycero-3-phosphocholine (GPC) with activated fatty acids, such as fatty acid imidazolides, is a standard procedure in phosphatidylcholine synthesis. It is usually carried out in the presence of DMSO anion with DMSO as solvent. No racemisation was reported.¹⁰




Scheme 4

(a) CDI, CHCl_3 ; (b) GPC, CdCl_2 , DMSO, DBU; 5 h, 56%


Thus in a slight variation of the literature procedure¹⁰ TTA 3 was activated as the imidazolide with *N,N'*-carbonyldiimidazole (CDI). *sn*-Glycero-3-phosphocholine (GPC), as the cadmium (II) adduct, in the presence of DBU (a hindered base which prevents racemisation) was reacted with this imidazolide affording after work-up and purification, the desired TTA-PC 18 as a yellowish waxy solid in 56% yield. Similarly, dTTA-PC 19 and tTTA-PC 20, were obtained in 65 and 57% yield respectively.

- 10 The synthesis of phosphatidylethanolamine (PE) derivative 1,2-ditetradecylthioacetyl-*sn*-glycero-3-phosphoethanolamine (TTA-PE, 21) is shown in Scheme 4. The analogues dTTA-PE 22 and tTTA-PE 23 were synthesized in an analogous manner.


46



TTA-PE 21




dTTA-PE 22



tTTA-PE 23


Slight modification to a procedure by Wang *et al.*¹¹ effected the required enzymatic transphosphatidylation from phosphatidylcholine to phosphatidylethanolamine.

47



TTA-PC 18

a



TTA-PE 21

Scheme 5

(a) PLD, 30°C, pH 6.5, biphasic system, ethanolamine, 4 h, 94%

Starting from synthesized TTA-PC 18, TTA-PE 21 was afforded in good yield (94%) as a pale yellow, waxy solid through enzymatic transphosphatidylolation with phospholipase D (PLD) in the presence of excess ethanolamine. Similarly, dTTA-PE 22 and tTTA-PE 23, were obtained in 89 and 86% yields respectively.


EXPERIMENTAL**General Procedure:**

10 Dried CH_2Cl_2 was distilled with phosphorous pentoxide, other solvents were purchased pre-dried as required. Thin layer chromatography (TLC) was performed on pre-coated Merck-Kieselgel 60 F_{254} aluminium backed plated and revealed with ultraviolet light, iodine, acidic ammonium molybdate(IV), acidic ethanolic vanillin, or other agents as appropriate. Flash column chromatography was accomplished on Merck-Kieselgel 60
15 (230-400 mesh). Infrared Spectra were recorded on Jasco FT/IR 620 using NaCl plates. Mass spectra were recorded using Bruker Esquire 3000, VG-7070B or JEOL SX-102 instruments. ^1H & ^{13}C NMR spectra were recorded on either Bruker DRX300, Advance

400 Ultrashield TM or Jeol GX-270Q machines using residual isotopic solvent as an internal reference (CHCl_3 , $\delta_{\text{H}} = 7.26$ ppm) (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet). All chemicals were purchased from Sigma-Aldrich or Lancaster if not otherwise stated.

5

Tetradecylthioacetic acid (TTA) 3




TTA 3

- 10 Thioacetic acid (3.32 g, 36.0 mmol) in MeOH (150 ml) was treated successively with NaOMe (25% in MeOH, 12g, 0.08 mol) and tetradecyl bromide (10.0 g, 0.036 mol) and stirred vigorously at room temperature for 48 h. The mixture was poured into H_2O , acidified to pH 2 (conc. HCl) and extracted with diethyl ether. Drying (MgSO_4) and concentration *in vacuo* afforded a crude solid which was purified by flash column
- 15 chromatography (FCC) (25% EtOAc in hexanes to 35% EtOAc in hexanes) to yield 3 as a colourless solid (8.6 g, 82%); m.p. 64-66°C (lit. 65-67°C); δ_{H} (300 MHz, CDCl_3) 0.89 (t, 3H, J 6.7 Hz), 1.27 (m, 22H), 1.32 (m, 2H), 1.61 (m, 2H), 2.67 (t, 2H, J 7.4) and 3.28 (s, 2H); MS (FAB⁺) 289 ($\text{M}+\text{H}$)⁺, 288 M^+ ; HRMS: Found M^+ 288.211823. Calc. for $\text{C}_{16}\text{H}_{32}\text{O}_2\text{S}$: M^+ 288.212302.


20

(6-Hydroxyhexyl)triphenylphosphonium bromide 6




6

- 25 6-Bromo-1-hexanol (5.0 g, 27.6 mmol) and triphenylphosphine (7.6 g, 28.2 mmol) in acetonitrile (100 ml) were refluxed for 6 days after which the solvent was removed *in vacuo* affording crude 6 (12.0 g, 98%); δ_{H} (300 MHz, CDCl_3) 1.53 (m, 4H), 1.69 (m, 4H), 3.65 (m, 2H), 3.73 (m, 3H), 7.7-7.9 (m, 15H).




(6-Hydroxyhexyl)triphenylphosphonium bromide **6** (0.5 g, 1.13 mmol) in warm DMSO (3 ml) was added to THF solution of methylsulfinylmethanide ion (prepared from NaH (57 mg, 2.37 mmol) and DMSO (1 ml) under N₂ at 70-75°C for 80 min) with cooling in an ice-bath. The bright yellow solution of phosphorane was stirred at room temperature for 10 min, then treated with octanal (0.159 g, 1.25 mmol) at 0°C. After stirring for 20 min, the reaction mixture was poured into 5 ml H₂O and extracted several times with ether. Drying with MgSO₄ and concentration afforded a residue which was purified by FCC (14% EtOAc in hexanes) to yield **7** (0.13 g, 54%, lit. 60%); δ_{H} (270 MHz, CDCl₃) 0.86 (3H, t, *J* 6.5 Hz), 1.10-1.43 (16H, m), 1.55 (2H, m), 2.00 (4H, m), 3.6 (2H, t, *J* 6.5 Hz) and 5.3-5.4 (2H, m).

cis-1-Bromo-tetradec-6-ene **8**



Alcohol **7** (115 mg, 0.541 mmol) in dichloromethane (100 ml) at 0°C was treated successively with carbon tetrabromide (395 mg, 1.20 mmol) and triphenylphosphine (312 mg, 1.20 mmol), and allowed to warm to room temperature with stirring over 2 h. The reaction mixture was triturated with water and extracted with methylene chloride, dried (MgSO₄) and concentrated *in vacuo*. The crude product was purified by flash column chromatography using hexanes as an eluent, thus affording pure **8** as a light oil (105 mg, 0.381 mmol, 70%); δ_{H} (270 MHz, CDCl₃) 0.87 (3H, t, *J* 6.1 Hz), 1.1-1.65 (14H, m), 1.85 (2H, quin, *J* 7.0), 2.03 (4H, m), 3.4 (2H, t, *J* 6.8) and 5.35 (4H, m); δ_{C} (67.5 MHz, CDCl₃) 27.06, 27.32, 27.72, 27.91, 28.04, 28.96, 29.32, 29.37, 29.71, 29.83, 31.96, 32.82, 34.01, 129.31, 130.47.

cis-Tetradec-6-enyl-1-thioacetic acid (dTTA) 4


dTTA 4

5

Thioacetic acid (35 mg, 0.38 mmol) in methanol (20 ml) was treated successively with sodium methoxide (50 mg, 0.9144 mmol) and bromide **8** (105 mg, 0.381 mmol) and stirred at r.t. for 2 d. The reaction mixture was diluted in water and acidified with cold conc. aq. HCl. The aqueous layer was extracted with hexanes, dried (MgSO₄) and concentrated *in vacuo* to afford a crude residue which was purified by flash column chromatography (eluent: gradient elution 65-75% EtOAc in Hexanes) to afford pure **4** as a viscous oil (105 mg, 0.367 mmol, 96%); δ_{H} (270 MHz, CDCl₃); 0.86 (3H, t, *J* 6.8), 1.35 (14H, m), 1.60 (2H, m), 2.00 (4H, m), 2.65 (2H, t, *J* 7.4), 3.24 (2H, s), 5.34 (2H, m) and 10.0 (1H, br s); δ_{C} (67.5 MHz, CDCl₃) 14.20, 22.76, 27.09, 27.31, 28.45, 28.89, 29.32, 29.35, 29.35, 29.83, 31.95, 32.82, 33.54, 129.44, 130.36 and 176.77; MS (CI) 304 (M+ NH₄)⁺; HRMS: Found [M+ NH₄]⁺ 304.230876. Calc. for C₁₆H₃₄NO₂S : [M+ NH₄]⁺ 304.231026.


2-(5-Iodopentyl-1-oxy)-tetrahydropyran 10

20



10


The title compound **10** was synthesized in 3 steps from 5-bromo-pentyl acetate **9** utilizing the method of Bestmann and Gunawardena¹⁰. Thus **9** (58.8 g, 0.281 mol) yielded pure iodide **10** (54.7 g, 0.183 mol, 65%); δ_{H} (270 MHz, CDCl₃); 1.40-1.90 (12H, m), 3.17 (2H, t, *J* 6.9), 3.30-3.55 (2H, m), 3.69-3.90 (2H, m) and 4.55 (1H, m); δ_{C} (67.5 MHz, CDCl₃) 7.05, 19.75, 25.54, 27.38, 28.74, 30.82, 33.42, 62.47, 67.28, 69.65, 73.45, 98.97 and 116.07; MS (EI) 297 (M-H)⁺; HRMS: Found [M-H]⁺ 297.034067. Calc. for C₁₀H₁₈O₂I : [M-H]⁺ 297.035157.

2-(Tetradec-6-ynyl-1-oxy)-tetrahydropyran 12

5

1-Nonyne 11 (1.0 g, 8.06 mmol) in THF (20 ml) was treated with n-BuLi (1.7 M in hexanes, 6.6 ml, 0.011 mmol) at 0°C and the resulting pale yellow solution stirred for a 15 min. HMPA (15 ml) was then added and the mixture stirred for a further 15 min at 0°C. To the resultant dark yellow/ orange solution was then added 10 (3.6 g, 0.0121 mol) at 0°C which resulted in a immediate colour change in the solution to light yellow. This light yellow solution was stirred at r.t. overnight at which stage it was triturated with water and extracted with hexanes. The hexane extract were well washed with water, dried (MgSO₄) and concentrated *invacuo* to afford a light yellow residue which was purified by flash column chromatography (8.5% EtOAc in hexanes) to yield pure 12 (1.6 g, 70%); δ_H (270 MHz, CDCl₃); 0.86 (3H, t, *J* 6.2), 1.15-1.85 (13H, m), 2.11 (4H, m), 3.30-3.55 (2H, m), 3.69-3.90 (2H, m) and 4.56 (1H, m); δ_C (67.5 MHz, CDCl₃) 14.17, 18.82, 18.82, 19.74, 22.71, 25.57, 25.57, 28.91, 28.91, 29.08, 29.24, 29.38, 30.49, 30.84, 31.84, 62.40, 62.40, 67.57, 67.57, 98.90. MS (EI) 295 (M+H)⁺; HRMS: Found 295.2616 [M+H]⁺. Calc. for C₁₉H₃₅O₂ : 295.263706 [M+H]⁺.


20

cis-1-Bromo-tetradec-6-ene 8

A mixture of alkyne 12 (150 mg, 0.509 mmol), quinoline (0.18 ml, 1.50 mmol) and Lindlar catalyst (Pd, 5% wt. % on calcium carbonate, poisoned with lead, 100 mg) was stirred under a H₂ atmosphere (balloon pressure) at room temperature for 3 h. After removal of the solids residues by filtration through Celite, the filtrate was washed with water and extracted with hexanes, dried (MgSO₄) and concentrated to afford a crude residue which was not purified. The residue was dissolved in dichloromethane at 0°C and the mixture treated successively with triphenylphosphine (52 mg, 0.20 mmol) and


triphenylphosphine dibromide (236 mg, 0.56 mmol), and the resultant mixture stirred for 1h at 0°C. The mixture was then washed with 10% aq. potassium carbonate, water and dried (MgSO₄). Concentration afforded a crude residue which was purified by flash column chromatography (hexanes) to afford pure **8** (81%); δ_H (270 MHz, CDCl₃); 0.87 (3H, t, *J* 6.1 Hz), 1.1-1.65 (14H, m), 1.85 (2H, quin, *J* 7.0), 2.03 (4H, m), 3.4 (2H, t, *J* 6.8) and 5.35 (4H, m); δ_C (67.5 MHz, CDCl₃) 27.06, 27.32, 27.72, 27.91, 28.04, 28.96, 29.32, 29.37, 29.71, 29.83, 31.96, 32.82, 34.01, 129.31, 130.47.

2-(10-Bromodecyl-1-oxy)-tetrahydropyran **14**

**14**

1-Bromodecan-1-ol **13** (5.0 g, 21.1 mmol) was treated with dihydropyran (2.14 g, 25.4 mmol) and pyridinium *p*-toluene sulfonate (0.1 g cat.) in anhydrous methylene chloride (100 ml) at 0°C and stirred at room temperature for 8 h. The reaction was quenched with 10% NaHCO₃ and extracted with methylene chloride. The organic extract was washed with brine and water and dried over anhydrous MgSO₄. The solvent was removed *in vacuo* to afford an oil which was purified by FCC (4-8% Et₂O in hexanes). Pure **14** was obtained as a viscous oil (5.0 g, 15.5 mmol, 73%); δ_H (270 MHz, CDCl₃) 1.27-1.91 (22H, m), 3.36 (2H, t, *J* 6.9 Hz), 3.34-3.90 (4H, m) and 4.55 (1H, m); MS (FAB⁺) 321 M⁺, HMRS: Found, 319.127007 (M-H⁺). Calc. for C₁₅H₂₈BrO₂, 319.127267 (M-H)⁺.


2-(Dodec-11-ynyl-1-oxy)tetrahydropyran **15**

**15**

Anhydrous DMSO (15 ml) was added to cooled lithium acetylide (1.47 g, 15.2 mmol) under a dry N₂ atmosphere. The mixture was stirred for 10 min at 5°C then treated dropwise with **14** (3 g, 11.5 mmol) in DMSO (4 ml). The resultant mixture was stirred at


5°C for 3 h, allowed to warm to room temperature overnight and then quenched with iced water followed by several extractions with ether. The ether extracts were washed several times with water, dried over MgSO_4 and concentrated *in vacuo* to give the crude product. Purification by FCC (4% EtOAc in hexanes) yielded pure **15** (1.95 g, 65%); δ_{H} (270 MHz, CDCl_3) 1.20-1.50 (12H, m), 1.50-1.88 (10H, m), 1.95 (1H, t, J 2.6 Hz), 2.19 (2H, dt, J 2.6, 7.0 Hz), 3.35-3.92 (4H, m) and 4.58 (1H, m); HRMS: Found, 267.231735 ($\text{M}+\text{H}$)⁺. Calc. for $\text{C}_{17}\text{H}_{31}\text{O}_2$: 267.232406 ($\text{M}+\text{H}$)⁺.

2-(Tetradec-11-ynyl-1-oxy)-tetrahydropyran **16**




Alkyne **16** was synthesized in an identical manner as alkyne **12**. Thus terminal alkyne **15** (5.09 g, 0.0191 mol) and ethyl iodide (5.46 g, 0.031 mol) yielded crude **16** which was not purified but used directly in the next step *i.e.* synthesis of bromide **17**.

14-Bromo-tetradec-3-yne **17**




20

The alkynyl ether **16** (5.62 g, 0.0191 mol) in dichloromethane (150 ml) at 0°C was treated successively with carbon tetrabromide (8.23 g, 0.0248 mol) and triphenylphosphine (13 g, 0.050 mol) and stirred for 5 h at r.t. The solution was treated with silica gel, the solvent removed *in vacuo* and the dry residue loaded onto a prepared flash column. Elution with hexanes yielded the pure bromide **17** (87% from **15**); δ_{H} (270 MHz, CDCl_3) 1.10 (3H, t, J 7.4), 1.27-1.54 (14H, m), 1.84 (2H, quin, J 7.3), 2.15 (4H, m) and 3.40 (2H, t, J 6.8). δ_{C} (100 MHz, CDCl_3) 12.82, 14.79, 27.28, 29.23, 29.26, 29.4, 29.53, 29.80, 29.80, 30.11, 33.04, 79.96 (quaternary) and 82.00 (quaternary).

Tetradec-11-ynyl-1-thioacetic acid (TTA) 5

TTA 5

- 5 Acid 5 was synthesized in an identical manner as compounds 3 and 4. Thus bromide 17 (4.4 g, 15.98 mmol) and thioacetic acid (1.5 g, 16.2 mmol) afforded crude acid which was crystallized from hexanes to yield pure acid 5 (3.90 g, 86%) as a white solid; δ_H (270 MHz, $CDCl_3$) 1.10 (3H, t, J 7.30), 1.20-1.50 (14 H), 1.60 (2H, m), 2.15 (4H, m), 2.64 (2H, t, J 7.30), 3.25 (2H, s) and 11.0 (1H, br s); δ_C (67.5 MHz, $CDCl_3$) 12.49, 14.47, 18.80, 28.80, 28.95, 28.95, 29.21, 29.21, 29.21, 29.51, 32.88, 33.56, 79.82, 81.80 and 176.51; MS (CI) 302 $[M+NH_4]^+$, HMRS: Found, 302.214964 $[M+NH_4]^+$. Calc. for $C_{16}H_{32}NO_2S$: 302.215376 $[M+NH_4]^+$.


1,2-Ditetradecylthioacetoyl-*sn*-glycero-3-phosphocholine (TTA-PC, 18)

TTA-PC 18

- To a stirred solution of TTA 3 (231 mg, 0.80 mmol) in anhydrous $CHCl_3$ (5 ml) was added N,N' -carbonyldiimidazole (CDI; 162 mg, 1.00 mmol) under a N_2 atmosphere. Meanwhile, *sn*-glycero-3-phosphocholine:cadmium (II) chloride adduct (GPC; 137 mg, 0.30 mmol, 1 eq.) was dissolved in DMSO (5 ml), with a little heating. To this solution was added DBU (120 ml, 0.80 mmol). The $CHCl_3$ solution was transferred to the DMSO solution *via* a cannula with further $CHCl_3$ (2 ml). After 7 h, the crude reaction mixture was neutralised with 0.1 M acetic acid (20 ml), then extracted into a 2:1 mixture of $CHCl_3$:MeOH (total volume 150 ml), and washed with a 1:1 mixture of H_2O :MeOH (100 ml \rightarrow 250 ml stepwise, over five washes), back-extracting each time. The subsequent organic fractions were combined and concentrated *in vacuo*, accompanying the water and

methanol with benzene. The residual orange-brown, viscous oil was purified by SiO₂ flash column chromatography [CH₂Cl₂:MeOH:H₂O, 77.54:20.23:2.23], to afford TTA-PC 18 as an off-white waxy solid (135 mg, 56 %): R_f 0.33 [CH₂Cl₂:MeOH:H₂O, 65:25:4]; ¹H NMR (270 MHz, CDCl₃) δ 0.82 (6 H, t, *J* = 6.5 Hz, 2 CH₂CH₃), 1.15 – 1.39 (44 H, 2 m, 22 CH₂), 1.47 – 1.65 (4 H, m, 2 CH₂CH₃), 2.54-2.61 (4 H, 2 x t, *J* = 7.2 Hz, 2 CH₂SCH₂CO₂), 3.20 and 3.23 (2 x 1 H, 2 s, 2 CH₂SCH₂CO₂), 3.34 (9 H, s, N(CH₃)₃) 3.59 – 3.67 (2 H, m, CH₂N(CH₃)₃), 3.87 – 3.98 (2 H, m, glycerol-C3-H_{a,b}), 4.07 – 4.15 (1 H, dd, ²*J* = 12.0 Hz, ³*J* = 7.8 Hz, glycerol-C1-H_b), 4.26 – 4.33 (2 H, m, CH₂CH₂N(CH₃)₃), 4.34 – 4.39 (1 H, dd, ²*J* = 12.0 Hz, ³*J* = 2.5 Hz, glycerol-C1-H_a), 5.13 – 5.22 (1 H, m, glycerol-C2-H), ¹³C NMR (67.5 MHz, CDCl₃) δ 170.44, 170.19 (2 CO), 71.66 (d, *J*_{CP} = 7.74 Hz, POCH₂CHCH₂), 66.30 (d, *J*_{CP} = 4.67 Hz, POCH₂CH₂N(CH₃)₃), 63.63 (POCH₂CHCH₂), 63.28 (d, *J*_{CP} = 25.2 Hz, POCH₂ [glycerol]), 59.38 (d, *J*_{CP} = 21.2 Hz, POCH₂ [choline]), 54.42 (N(CH₃)₃), 33.66, 33.50, 32.80, 32.73, 29.77 (40 x CH₂), 29.43, 28.91, 28.89, 28.89, 22.75, 14.18 (2 CH₃); *m/z* (FAB+) 820 ([M + Na]⁺), 798 ([M+H]⁺); HRMS: Calculated for C₄₀H₈₁NO₈PS₂:798.514126.Found:798.510895 ([M+H]⁺).

1,2-Di(*Cis*-tetradec-6'-enyl-1'-thioacetyl)-*sn*-glycero-3-phosphocholine (dTTA-PC, 19)



dTTA-PC 19

20

To a stirred solution of dTTA 4 (229 mg, 0.80 mmol) in anhydrous CHCl₃ (5 ml) was added *N,N'*-carbonyldiimidazole (CDI; 162 mg, 1.00 mmol) under a N₂ atmosphere. Meanwhile, *sn*-glycero-3-phosphocholine:cadmium (II) chloride adduct (GPC; 137 mg, 0.30 mmol, 1 eq.) was dissolved in DMSO (5 ml), with a little heating. To this solution was added DBU (120 ml, 0.80 mmol). The CHCl₃ solution was transferred to the DMSO solution *via* a cannula with further CHCl₃ (2 ml). After 7 h, the crude reaction mixture was neutralised with 0.1 M acetic acid (20 ml), then extracted into a 2:1 mixture of CHCl₃:MeOH (total volume 150 ml), and washed with a 1:1 mixture of H₂O:MeOH (100


25

ml → 250 ml stepwise, over five washes), back-extracting each time. The subsequent organic fractions were combined, and concentrated *in vacuo*, azeotroping the water and methanol with benzene. The residual orange-brown, viscous oil was purified by SiO₂ flash column chromatography [CH₂Cl₂:MeOH:H₂O, 77.54:20.23:2.23], to afford dTTA-

- 5 PC 19 as an off-white waxy solid (155 mg, 65 %): R_f 0.33 [CH₂Cl₂:MeOH:H₂O, 65:25:4]; ¹H NMR (270 MHz, CDCl₃) δ 0.82 (6 H, t, *J* = 6.5 Hz, 2 CH₂CH₃), 1.15 – 1.39 (28 H, 2 m, 14 CH₂), 1.47 – 1.65 (4 H, m, 2 CH₂CH₃), 1.92 – 2.07 (8 H, m, 2 CH₂CH=CHCH₂), 2.54–2.61 (4 H, 2 x t, *J* = 7.2 Hz, 2 CH₂SCH₂CO₂), 3.20 and 3.23 (2 x 1 H, 2 s, 2 CH₂SCH₂CO₂), 3.34 (9 H, s, N(CH₃)₃) 3.59 – 3.67 (2 H, m, CH₂N(CH₃)₃),
 10 3.87 – 3.98 (2 H, m, glycerol-C3-H_{a,b}), 4.07 – 4.15 (1 H, dd, ²*J* = 12.0 Hz, ³*J* = 7.8 Hz, glycerol-C1-H_b), 4.26 – 4.33 (2 H, m, CH₂CH₂N(CH₃)₃), 4.34 – 4.39 (1 H, dd, ²*J* = 12.0 Hz, ³*J* = 2.5 Hz, glycerol-C1-H_a), 5.13 – 5.27 (1 H, m, glycerol-C2-H) and 5.25 – 5.38 (4 H, m, 2 CH=CH); ¹³C NMR (67.5 MHz, CDCl₃) δ 170.36, 170.09 (2 CO), 130.29, 129.38 (2 C=C), 71.58 (d, *J*_{CP} = 7.74 Hz, POCH₂CHCH₂), 66.30 (d, *J*_{CP} = 4.67 Hz, POCH₂CH₂N(CH₃)₃), 63.63 (POCH₂CHCH₂), 63.16 (d, *J*_{CP} = 25.2 Hz, POCH₂ [glycerol]), 59.38 (d, *J*_{CP} = 21.2 Hz, POCH₂ [choline]), 54.42 (N(CH₃)₃), 33.60, 33.46, 32.72, 32.64, 31.91, 29.77, 29.40, 29.32, 29.28, 28.96, 28.47, 27.29, 27.11, 22.75 and 14.18 (2 CH₃); *m/z* (FAB+) 816 ([M + Na]⁺), 794 ([M+H]⁺); HRMS: Calculated for C₄₀H₇₇NO₈PS₂:794.482826. Found:794.480957 ([M+H]⁺).

20

1,2-Di(tetradec-11'-ynyl-1'-thioacetoyl)-*sn*-glycero-3-phosphocholine (tTTA-PC, 20)




tTTA-PC 20

- 25 To a stirred solution of tTTA 5 (228 mg, 0.80 mmol) in anhydrous CHCl₃ (5 ml) was added *N,N'*-carbonyldiimidazole (CDI; 162 mg, 1.00 mmol) under a N₂ atmosphere. Meanwhile, *sn*-glycero-3-phosphocholine:cadmium (II) chloride adduct (GPC; 137 mg, 0.30 mmol, 1 eq.) was dissolved in DMSO (5 ml), with a little heating. To this solution

was added DBU (120 ml, 0.80 mmol). The CHCl_3 solution was transferred to the DMSO solution *via* a cannula with further CHCl_3 (2 ml). After 7 h, the crude reaction mixture was neutralised with 0.1 M acetic acid (20 ml), then extracted into a 2:1 mixture of CHCl_3 :MeOH (total volume 150 ml), and washed with a 1:1 mixture of H_2O :MeOH (100 ml \rightarrow 250 ml stepwise, over five washes), back-extracting each time. The subsequent organic fractions were combined, and concentrated *in vacuo*, azeotroping the water and methanol with benzene. The residual orange-brown, viscous oil was purified by SiO_2 flash column chromatography [CH_2Cl_2 :MeOH: H_2O , 77.54:20.23:2.23], to afford tTTA-PC **20** as an off-white waxy solid (135 mg, 57 %): R_f 0.33 [CH_2Cl_2 :MeOH: H_2O , 65:25:4]; ^1H NMR (270 MHz, CDCl_3) δ 1.09 (6 H, t, $J = 6.9$ Hz, 2 CH_2CH_3), 1.15 – 1.60 (32 H, m, 16 CH_2), 2.0 – 2.17 ($\text{CH}_2\text{C}\equiv\text{CCH}_2$), 2.56 (4 H, 2 x t, $J = 7.2$ Hz, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.20 and 3.23 (2 x 1 H, 2 s, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.34 (9 H, s, $\text{N}(\text{CH}_3)_3$), 3.59 – 3.67 (2 H, m, $\text{CH}_2\text{N}(\text{CH}_3)_3$), 3.87 – 3.98 (2 H, m, glycerol-C3- H_{ab}), 4.07 – 4.15 (1 H, dd, $^2J = 12.0$ Hz, $^3J = 7.8$ Hz, glycerol-C1- H_{b}), 4.26 – 4.33 (2 H, m, $\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$), 4.34 – 4.39 (1 H, dd, $^2J = 12.0$ Hz, $^3J = 2.5$ Hz, glycerol-C1- H_{a}), 5.13 – 5.27 (1 H, m, glycerol-C2- H); ^{13}C NMR (67.5 MHz, CDCl_3) δ 170.36, 170.09 (2 CO), 81.6 and 79.58 (2 $\text{C}\equiv\text{C}$), 71.61 (d, $J_{\text{CP}} = 7.74$ Hz, $\text{POCH}_2\text{CHCH}_2$), 66.35 (d, $J_{\text{CP}} = 4.67$ Hz, $\text{POCH}_2\text{CH}_2\text{N}(\text{CH}_3)_3$), 63.65 ($\text{POCH}_2\text{CHCH}_2$), 63.22 (d, $J_{\text{CP}} = 25.2$ Hz, POCH_2 [glycerol]), 59.33 (d, $J_{\text{CP}} = 21.2$ Hz, POCH_2 [choline]), 54.47 ($\text{N}(\text{CH}_3)_3$), 33.64, 33.50, 32.79, 32.72, 29.56, 29.56, 29.32, 29.21, 29.21, 29.03, 28.92, 28.87, 18.76, 14.45 and 12.46 (2 CH_3); m/z (FAB+) 812 ($[\text{M} + \text{Na}]^+$), 790 ($[\text{M} + \text{H}]^+$); HRMS: Calculated for $\text{C}_{40}\text{H}_{73}\text{NO}_8\text{PS}_2$: 790.451526. Found: 790.453156 ($[\text{M} + \text{H}]^+$).

1,2-Ditetradecylthioacetoyl-sn-glycero-3-phosphoethanolamine (TTA-PE, **21**)


25

TTA-PE **21**

A solution of ethanolamine (91 ml, 1.50 mmol, 6 eq.) in a 100 mM NaOAc / 50 mM CaCl_2 buffer (0.625 ml) at pH 6.5 (pH adjusted with acetic acid), was added to a stirred

solution of **18** (135 mg, 0.169 mmol, 1 eq.) in CHCl_3 (5 ml) at 30 °C. To this biphasic system was added PLD (310 units in 440 ml of the aforementioned buffer, pH 6.5), and the reaction mixture was allowed to stir at 30 °C for 3 h. Further PLD (35 units) was added. After 10 h, the aqueous phase was diluted to 15 ml, and the crude organic material was extracted by washing with CHCl_3 :MeOH, 2:1 (30 ml x 3). The organic layers were combined and washed with H_2O (15 ml), then concentrated *in vacuo*, and subjected to SiO_2 flash column chromatography [CH_2Cl_2 :MeOH: H_2O , 77.54:20.23:2.23] to purify. This afforded the title compound, **21**, as a very pale-yellow, waxy solid (120 mg, 94 %): R_f 0.32 [CH_2Cl_2 :MeOH: H_2O , 65:25:4]; ^1H NMR (400 MHz, CDCl_3) δ 0.85 (6 H, t, J = 6.9 Hz, 2 CH_2CH_3), 1.15 – 1.41 (44 H, 2 m, 22 CH_2), 1.50 – 1.62 (4 H, m, 2 CH_2CH_3), 2.58 (4 H, 2 t, J = 6.9 Hz, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.05 – 3.13 (2 H, m, CH_2NH_3), 3.20 and 3.24 (2 H, 2 s, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.85 – 3.91 (2 H, m, glycerol-C3- $\text{H}_{a,b}$), 3.97 – 4.05 (2 H, m, $\text{CH}_2\text{CH}_2\text{NH}_3$), 4.09 – 4.14 (1 H, dd, 2J = 12.0 Hz, 3J = 6.4 Hz, glycerol-C1- H_b), 4.30 – 4.35 (1 H, dd, 2J = 11.8 Hz, 3J = 2.6 Hz, glycerol-C1- H_a), 5.14 – 5.20 (1 H, m, glycerol-C2-H), 8.20 – 8.60 (br s, NH_3); ^{13}C NMR (400 MHz, CDCl_3) δ 170.29, 170.13 (2 CO), 71.28 (d, J_{CP} = 27.6 Hz, $\text{POCH}_2\text{CHCH}_2$), 63.73 (d, J_{CP} = 22.0 Hz, POCH_2 [glycerol]), 63.25 ($\text{POCH}_2\text{CHCH}_2$), 62.40 (m, POCH_2 [choline]), 40.49 (CH_2NH_3), 33.59, 33.42, 32.81, 32.75, 32.01, 29.81 (14 CH_2), 29.46, 29.09, 28.97, 28.93, 22.77 and 14.19.

1,2-Di(*Cis*-tetradec-6'-enyl-1'-thioacetyl)-sn-glycero-3-phosphoethanolamine (dTTA-PE, **22**)



dTTA-PE **22**

A solution of ethanolamine (91 ml, 1.50 mmol, 6 eq.) in a 100 mM NaOAc / 50 mM CaCl_2 buffer (0.625 ml) at pH 6.5 (pH adjusted with acetic acid), was added to a stirred solution of **19** (188 mg, 0.237 mmol, 1 eq.) in CHCl_3 (5 ml) at 30 °C. To this biphasic system was added PLD (250 units in 440 ml of the aforementioned buffer, pH 6.5), and the reaction mixture was allowed to stir at 30 °C for 3 h. Further PLD (35 units) was

added. After 10 h, the aqueous phase was diluted to 15 ml, and the crude organic material was extracted by washing with $\text{CHCl}_3\text{:MeOH}$, 2:1 (30 ml x 3). The organic layers were combined and washed with H_2O (15 ml), then concentrated *in vacuo*, and subjected to SiO_2 flash column chromatography [$\text{CH}_2\text{Cl}_2\text{:MeOH:H}_2\text{O}$, 77.54:20.23:2.23] to purify.


5 This afforded the title compound, **22**, as a very pale-yellow, waxy solid (158 mg, 89 %): R_f 0.32 [$\text{CH}_2\text{Cl}_2\text{:MeOH:H}_2\text{O}$, 65:25:4]; ^1H NMR (400 MHz, CDCl_3) δ 0.85 (6 H, t, J = 6.9 Hz, 2 CH_2CH_3), 1.15 – 1.41 (36 H, 2 m, 18 CH_2), 1.50 – 1.62 (4 H, m, 2 CH_2CH_3), 1.90 – 1.21 (8 H, m, 2 $\text{CH}_2\text{CH=CHCH}_2$), 2.58 (4 H, 2 t, J = 6.9 Hz, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.05 – 3.13 (2 H, m, CH_2NH_3), 3.20 and 3.24 (2 H, 2 s, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 9 Hz, 2

10 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.05 – 3.13 (2 H, m, CH_2NH_3), 3.20 and 3.24 (2 H, 2 s, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.85 – 3.91 (2 H, m, glycerol-C3- $\text{H}_{a,b}$), 3.97 – 4.05 (2 H, m, $\text{CH}_2\text{CH}_2\text{NH}_3$), 4.09 – 4.14 (1 H, dd, 2J = 12.0 Hz, 3J = 6.4 Hz, glycerol-C1- H_b), 4.30 – 4.35 (1 H, dd, 2J = 11.8 Hz, 3J = 2.6 Hz, glycerol-C1- H_a), 5.14 – 5.20 (1 H, m, glycerol-C2-H), 5.22 – 5.32 (4 H, m, 2 CH=CH), 8.20 – 8.60 (br s, NH_3); ^{13}C NMR (400 MHz, CDCl_3) δ 170.28, 170.11 (2 CO),

15 130.29, 129.41 (2 C=C), 71.28 (d, J_{CP} = 27.6 Hz, $\text{POCH}_2\text{CHCH}_2$), 63.73 (m, POCH_2 [glycerol]), 63.25 ($\text{POCH}_2\text{CHCH}_2$), 62.40 (m, POCH_2 [choline]), 40.49 (CH_2NH_3), 33.58, 33.41, 32.72, 32.67, 31.94, 29.82, 29.46, 29.35, 29.31, 28.99, 28.55, 28.52, 27.32, 27.16, 22.75 and 14.18 (2 CH_3); m/z (FAB+) 748 ($[\text{M} + \text{Na}]^+$), 770 ($[\text{M} + \text{H}]^+$); HRMS: Calculated for $\text{C}_{37}\text{H}_{67}\text{NO}_8\text{PS}_2$: 748.404576. Found: 748.404526 ($[\text{M} + \text{H}]^+$).

20

1,2-Di(tetradec-11'-ynyl)-1'-thioacetoyl)- sn-glycero-3-phosphoethanolamine (tTTA-PE, **23**)



tTTA-PE 23

25

A solution of ethanolamine (91 ml, 1.50 mmol, 6 eq.) in a 100 mM NaOAc / 50 mM CaCl_2 buffer (0.625 ml) at pH 6.5 (pH adjusted with acetic acid), was added to a stirred solution of **20** (185 mg, 0.234 mmol, 1 eq.) in CHCl_3 (5 ml) at 30 °C. To this biphasic

system was added PLD (250 units in 440 ml of the aforementioned buffer, pH 6.5), and the reaction mixture was allowed to stir at 30 °C for 3 h. Further PLD (35 units) was added. After 10 h, the aqueous phase was diluted to 15 ml, and the crude organic material was extracted by washing with CHCl_3 :MeOH, 2:1 (30 ml x 3). The organic layers were combined and washed with H_2O (15 ml), then concentrated *in vacuo*, and subjected to SiO_2 flash column chromatography [CH_2Cl_2 :MeOH: H_2O , 77.54:20.23:2.23] to purify. This afforded the title compound, **23**, as a very pale-yellow, waxy solid (151 mg, 86 %): R_f 0.32 [CH_2Cl_2 :MeOH: H_2O , 65:25:4]; ^1H NMR (400 MHz, CDCl_3) δ 1.09 (6 H, t, J = 6.9 Hz, 2 CH_2CH_3), 1.15 – 1.60 (32 H, m, 8 CH_2), 2.0 – 2.17 ($\text{CH}_2\text{C}\equiv\text{CCH}_2$), 2.56 (4 H, 2 x t, J = 7.2 Hz, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.05 – 3.13 (2 H, m, CH_2NH_3), 3.20 and 3.23 (2 x 1 H, 2 s, 2 $\text{CH}_2\text{SCH}_2\text{CO}_2$), 3.85 – 3.91 (2 H, m, glycerol-C3- $\text{H}_{a,b}$), 3.97 – 4.05 (2 H, m, $\text{CH}_2\text{CH}_2\text{NH}_3$), 4.09 – 4.14 (1 H, dd, 2J = 12.0 Hz, 3J = 6.4 Hz, glycerol-C1- H_b), 4.30 – 4.35 (1 H, m, glycerol-C1- H_a), 5.14 – 5.20 (1 H, m, glycerol-C2- H), 8.20 – 8.60 (br s, NH_3); ^{13}C NMR (67.5 MHz, CDCl_3) δ 170.27, 170.11 (2 CO), 81.60 and 79.58 (2 $\text{C}\equiv\text{C}$), 71.28 (d, J_{CP} = 27.6 Hz, $\text{POCH}_2\text{CHCH}_2$), 63.70 (d, J_{CP} = 22.0 Hz, POCH_2 [glycerol]), 63.22 ($\text{POCH}_2\text{CHCH}_2$), 62.35 (m, POCH_2 [choline]), 40.47 (CH_2NH_3), 33.58, 33.41, 32.78, 32.72, 29.61 (3 CH_2), 29.56, 29.37, 29.23 (3 CH_2), 29.04, 28.95 (2 CH_2), 28.88, 18.79, 14.45 and 12.47 (2 CH_3).

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims

2.4 REFERENCES

- 1a. PCT/NO01/00082
1b. PCT/NO99/00135
5 1c. PCT/NO99/00136
1d. PCT/NO99/00149
2. Berg, R.K. and Hvattuu, E.; *Pharmac. Ther.* (1994), **61**, 345.
3. Skrede, S. *et al*; *Biochim. Biophys. Acta* (1997), **1344**, 115.
4. EP 345.038
10 5. PCT/NO95/00195
6. PCT/NO01/00301
7. Horiike, M; Masaru, T. and Hirano, C.; *Agric. Biol. Chem.*, (1978), **42**(10), 1963.
8. Skarma, A.; Chattopadhyay, J.; *J. Org. Chem.*, (1998), **63**, 6128.
9. Jayasuriya, N.; Bosak, S.; Regan, S.L.; *J. Am. Chem. Soc.*, (1990), **112**, 5844.
15 10. A. Hermetter and F. Paltauf; *Chemistry and Physics of Lipids*, (1981), **28**, 111-115.
11. Wang, P., Schuster, M. Wang, Y.F., Wong, C.H. *J. Am. Chem Soc.* (1993), **115**,
10487-10491.
12. Bestmann and Gunawarden; *Synthesis*, (1992), 1239.

CLAIMS

1. A lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula

5 X-Y-Z-


wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO₂, SO, O, CH₂, and Z is an optional hydrocarbyl group, wherein when Y is CH₂, the chain X-Y-Z contains an even number of atoms;

wherein the polar moiety is of the formula

10 $-\text{[C(O)]}_m\text{PHG}$


wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

2. A compound according to claim 1 wherein the compound is of the formula



15 wherein p is from 1 to 10, preferably 1, 2 or 3, and wherein each X, Y and Z is selected independently of each other.


3. A compound according to claim 1 wherein the compound is of the formula



20

4. A compound according to claim 1 comprising at least two non-polar moieties wherein each is independently selected from non-polar moieties of the formula X-Y-Z-.


5. A compound according to claim 2 wherein the compound is of the formula



25

wherein each X, Y and Z is selected independently of each other.

6. A compound according to claim 4 wherein the compound is of the formula



wherein each X, Y and Z is selected independently of each other.

7. A compound according to any one of the preceding claims wherein the polar head group is derived from one of phospholipids, ceramides, triacylglycerols, lysophospholipids, phosphatidylserines, glycerols, alcohols, alkoxy compounds, monoacylglycerols, gangliosides, sphingomyelins, cerebroside, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols (PI), diacylglycerols, Phosphatidic acids, glycerocarbohydrates, polyalcohols and phosphatidylglycerols.
8. A compound according to claim 7 wherein the polar head group is derived from a phospholipid.
9. A compound according to claim 8 wherein the phospholipid is a neutral or anionic phospholipid.
10. A compound according to claim 8 wherein the phospholipid is selected from phosphatidylcholine (PC) and phosphatidylethanolamine (PE).
11. A compound according to any one of the preceding claims wherein the polar head group (PHG) is of the formula -W-Linker-HG, wherein W is selected from CH₂, O, NR¹ and S, wherein R¹ is H or a hydrocarbyl group, wherein Linker is an optional linker group, and HG is a head group.
12. A compound according to any one of the preceding claims wherein X is a group selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl.
13. A compound according to any one of the preceding claims wherein X is a group selected from unsubstituted alkyl, unsubstituted alkenyl and unsubstituted alkynyl.

14. A compound according to any one of the preceding claims wherein X is a group selected from unsubstituted C₆-C₂₄ alkyl, unsubstituted C₆-C₂₄ alkenyl and unsubstituted C₆-C₂₄ alkynyl.
- 5 15. A compound according to any one of the preceding claims wherein X is a group selected from unsubstituted C₁₀-C₁₈ alkyl, unsubstituted C₁₀-C₁₈ alkenyl and unsubstituted C₁₀-C₁₈ alkynyl.
- 10 16. A compound according to any one of the preceding claims wherein X is a group selected from unsubstituted C₁₄ alkyl, unsubstituted C₁₄ alkenyl and unsubstituted C₁₄ alkynyl.
17. A compound according to any one of the preceding claims wherein X is a hydrocarbon chain.
- 15 18. A compound according to any one of the preceding claims wherein Y is selected from S, Se, SO₂, SO, and O.
19. A compound according to any one of the preceding claims wherein Y is selected from S and Se.
- 20 20. A compound according to claim 19 wherein Y is S.
21. A compound according to any one of the preceding claims wherein Z is an alkyl group.
- 25 22. A compound according to any one of the preceding claims wherein Z is a C₁-C₁₀, preferably C₁-C₆, preferably C₁-C₃ alkyl group.
- 30 23. A compound according to any one of the preceding claims wherein Z is -CH₂-.
24. A compound according to any one of the preceding claims wherein Y-Z together represent the group
[Y¹-CH₂]_n

wherein Y^1 is selected from S, Se, SO_2 , SO, O, CH_2 , wherein when Y^1 is CH_2 , the chain X-Y-Z contains an even number of atoms, and
 wherein n is an integer from 1 to 20

5 25. A compound according to claim 24 wherein Y^1 is selected from S, Se, SO_2 , SO, and O.


26. A compound according to claim 25 wherein Y^1 is selected from S and Se.

10 27. A compound according to claim 26 wherein Y^1 is S.

28. A compound according to any one of claims 24 to 26 wherein n is from 1 to 10, preferably from 1 to 5, preferably 1, 2 or 3.


15 29. A compound according to any one of claims 24 to 27 wherein n is 1.

30. A compound according to claim 1 wherein the compound is of the formula




20 wherein Y^2 and Y^3 are independently S or Se, and X^2 and X^3 are independently selected from unsubstituted C_{10} - C_{18} alkyl, unsubstituted C_{10} - C_{18} alkenyl and unsubstituted C_{10} - C_{18} alkynyl.

31. A compound according to claim 1 wherein the compound is of the formula




X^2 and X^3 are independently selected from unsubstituted C_{10} - C_{18} alkyl, unsubstituted C_{10} - C_{18} alkenyl and unsubstituted C_{10} - C_{18} alkynyl.

32. A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from unsubstituted C_{14} alkyl, unsubstituted C_{14} alkenyl and unsubstituted C_{14} alkynyl.

33. A compound according to claim 1 wherein the compound is of the formula



X^2 and X^3 are independently selected from $CH_3(CH_2)_{13}-$, $CH_3(CH_2)_6CH=CH(CH_2)_5-$, and $CH_3CH_2C\equiv C(CH_2)_{10}-$.

34. A compound according to claim 30, 31, 32 or 33 wherein the polar head group is derived from the polar head group of a phospholipid.

35. A compound according to claim 34 wherein the phospholipid is a phosphatidylcholine (PC) or a phosphatidylethanolamine (PE).

36. A combination comprising a liposome and a compound according to any one of claims 1 to 35.

37. A pharmaceutical composition comprising a compound according to any one of claims 1 to 35 or a combination according to claim 36 optionally admixed with a

pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

38. A topically administrable pharmaceutical composition according to claim 37.
- 5 39. A parenterally administrable pharmaceutical composition according to claim 37.
40. An intravenously administrable pharmaceutical composition according to claim 39.
- 10 41. Use of a compound according to any one of claims 1 to 35 or a combination according to claim 36 in medicine.
42. Use of a compound according to any one of claims 1 to 35 in the manufacture of a medicament for the treatment and/or prevention of a condition selected from syndrome
- 15 X, obesity, hypertension, fatty liver, diabetes, hyperglycaemia, hyperinsulinemia and stenosis.
43. Use of a compound according to any one of claims 1 to 35 in the manufacture of a medicament for lowering concentration of cholesterol and triglycerides in the blood of
- 20 mammals and/or inhibiting the oxidative modification of low density lipoprotein.
44. A method for producing weigh loss or a reduction of the fat mass in a human or non-human animal in need thereof, comprising administering thereto an effective amount of a compound according to any one of claims 1 to 35.

ABSTRACT

COMPOUND

5

The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X-Y-Z- wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO₂, SO, O, CH₂, and
10 Z is an optional hydrocarbyl group, wherein when Y is CH₂, the chain X-Y-Z contains an even number of atoms; wherein the polar moiety is of the formula -[C(O)]_mPHG wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

THE PATENT OFFICE

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.